1
|
Loap P, Giorgi M, Vu-Bezin J, Kirov K, Sampai JM, Prezado Y, Kirova Y. Dosimetric feasibility study ("proof of concept") of refractory ventricular tachycardia radioablation using proton minibeams. Cancer Radiother 2024; 28:195-201. [PMID: 38599941 DOI: 10.1016/j.canrad.2024.02.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 02/15/2024] [Accepted: 02/16/2024] [Indexed: 04/12/2024]
Abstract
PURPOSE Preclinical data demonstrated that the use of proton minibeam radiotherapy reduces the risk of toxicity in healthy tissue. Ventricular tachycardia radioablation is an area under clinical investigation in proton beam therapy. We sought to simulate a ventricular tachycardia radioablation with proton minibeams and to demonstrate that it was possible to obtain a homogeneous coverage of an arrhythmogenic cardiac zone with this technique. MATERIAL AND METHODS An arrhythmogenic target volume was defined on the simulation CT scan of a patient, localized in the lateral wall of the left ventricle. A dose of 25Gy was planned to be delivered by proton minibeam radiotherapy, simulated using a Monte Carlo code (TOPAS v.3.7) with a collimator of 19 0.4 mm-wide slits spaced 3mm apart. The main objective of the study was to obtain a plan ensuring at least 93% of the prescription dose in 93% of the planning target volume without exceeding 110% of the prescribed dose in the planning target volume. RESULTS The average dose in the planning treatment volume in proton minibeam radiotherapy was 25.12Gy. The percentage of the planning target volume receiving 93% (V93%), 110% (V110%), and 95% (V95%) of the prescribed dose was 94.25%, 0%, and 92.6% respectively. The lateral penumbra was 6.6mm. The mean value of the peak-to-valley-dose ratio in the planning target volume was 1.06. The mean heart dose was 2.54Gy versus 5.95Gy with stereotactic photon beam irradiation. CONCLUSION This proof-of-concept study shows that proton minibeam radiotherapy can achieve a homogeneous coverage of an arrhythmogenic cardiac zone, reducing the dose at the normal tissues. This technique, ensuring could theoretically reduce the risk of late pulmonary and breast fibrosis, as well as cardiac toxicity as seen in previous biological studies in proton minibeam radiotherapy.
Collapse
Affiliation(s)
- P Loap
- Department of Radiation Oncology, institut Curie, Paris, France
| | - M Giorgi
- Signalisation radiobiologie et cancer, Inserm U1021, CNRS UMR3347, Institut Curie, université PSL, 91400 Orsay, France; Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Lisboa, Portugal; Departamento de Física, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
| | - J Vu-Bezin
- Department of Radiation Oncology, institut Curie, Paris, France
| | - K Kirov
- Department of Anesthesia and Reanimation, institut Curie, Paris, France
| | - J M Sampai
- Laboratório de Instrumentação e Física Experimental de Partículas (LIP), Lisboa, Portugal; Departamento de Física, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
| | - Y Prezado
- Signalisation radiobiologie et cancer, Inserm U1021, CNRS UMR3347, Institut Curie, université PSL, 91400 Orsay, France
| | - Y Kirova
- Department of Radiation Oncology, institut Curie, Paris, France; Université Versailles, Saint-Quentin, France.
| |
Collapse
|
2
|
Sitthiangkool P, Poapolathep A, Chomcheun T, Jongkolpath O, Khidkhan K, Klangkaew N, Phaochoosak N, Giorgi M, Poapolathep S. Pharmacokinetic characteristics of florfenicol in green sea turtles (Chelonia mydas) and hawksbill sea turtles (Eretmochelys imbricata) after intramuscular administration. J Vet Pharmacol Ther 2024. [PMID: 38520083 DOI: 10.1111/jvp.13441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 02/21/2024] [Accepted: 03/10/2024] [Indexed: 03/25/2024]
Abstract
The pharmacokinetics of florfenicol (FFC) in green sea and hawksbill sea turtles were evaluated following intramuscular (i.m.) administration at two different dosages of 20 or 30 mg/kg body weight (b.w.). This study (longitudinal design) used 5 green sea and 5 hawksbill sea turtles for the two dosages. Blood samples were collected at assigned times up to 168 h. FFC plasma samples were analyzed using validated high-performance liquid chromatography equipped with diode array detection. The pharmacokinetic analysis was performed using a non-compartment approach. The FFC plasma concentrations increased with the dosage. The elimination half-life was similar between the treatment groups (range 19-25 h), as well as the plasma protein binding (range 18.59%-20.65%). According to the surrogate PK/PD parameter (T > MIC, 2 μg/mL), the 20 and 30 mg/kg dosing rates should be effective doses for susceptible bacterial infections in green sea and hawksbill sea turtles.
Collapse
Affiliation(s)
- Pandaree Sitthiangkool
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Thanaphan Chomcheun
- Eastern Marine and Coastal Resources Research and Development Center, Rayong, Thailand
| | - Oranee Jongkolpath
- Eastern Marine and Coastal Resources Research and Development Center, Rayong, Thailand
| | - Kraisiri Khidkhan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Napasorn Phaochoosak
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Italy
| | - Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
3
|
Fadel C, Łebkowska-Wieruszewska B, Poapolathep A, Serih F, Bourdo K, Giorgi M. Pharmacokinetic evaluation of oral deracoxib in geese (Anser anser domesticus). J Vet Pharmacol Ther 2024. [PMID: 38421059 DOI: 10.1111/jvp.13435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 02/09/2024] [Accepted: 02/19/2024] [Indexed: 03/02/2024]
Abstract
The integration of pain management in veterinary practice, driven by heightened animal welfare concerns, extends to avian species where subtle and nonspecific behavioral signs pose challenges. Given that safety concerns with classical NSAIDs highlight the need for more targeted alternatives in birds, this study explores the pharmacokinetic (PK) properties of Deracoxib (DX), a COX-2 selective NSAID approved for use in dogs, following a single oral administration in geese. Six healthy female geese received 4 mg/kg DX. Blood was drawn from the left wing vein to heparinized tubes at 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h. Plasma DX concentrations were measured using HPLC coupled to an UV detector, and the data were pharmacokinetically analyzed using PKanalix™ software in a non-compartmental approach. The results indicated a terminal half-life of 6.3 h and a Tmax of 1 h, with no observed adverse effects. While refraining from claiming absolute safety based on a single dose, it is worth highlighting that further safety studies for DX in geese are warranted, suggesting a possibility for intermittent use. In addition, drawing conclusions on efficacy and suitability awaits further research, particularly in understanding COX-2 selectivity and protein binding characteristics specific to geese.
Collapse
Affiliation(s)
- Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
- Department of Veterinary Medicine, Lebanese University, Beirut, Lebanon
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Firas Serih
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | | | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| |
Collapse
|
4
|
Yalong M, Poapolathep S, Giorgi M, Khidkhan K, Klangkaew N, Phaochoosak N, Chaiyabutr N, Wongwaipairoj T, Poapolathep A. Pharmacokinetic disposition of marbofloxacin after intramuscular administration in estuarine crocodiles (Crocodylus porosus). J Vet Pharmacol Ther 2024; 47:48-53. [PMID: 37381629 DOI: 10.1111/jvp.13400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Revised: 06/09/2023] [Accepted: 06/19/2023] [Indexed: 06/30/2023]
Abstract
To date, the pharmacokinetics of fluoroquinolones in estuarine crocodiles (Crocodylus porosus) have been reported for enrofloxacin but not for marbofloxacin (MBF), which is a broad-spectrum antibiotic used only in veterinary medicine. This study investigated the pharmacokinetics of MBF after intramuscular administration at two difference dosages (2 and 4 mg/kg body weight) in estuarine crocodiles and estimated pharmacokinetic/pharmacodynamic (PK/PD) surrogate parameters for the optimization of dosage regimens. Ten treated estuarine crocodiles were divided into two groups (n = 5) using a randomization procedure according to a parallel study design. Blood samples were collected at assigned times up to 168 h. MBF plasma samples were cleaned up using liquid-liquid extraction and analyzed using a validated high-performance liquid chromatography method with fluorescence detection. A non-compartment approach was used to fit the plasma concentration of MBF vs time curve for each crocodile. The plasma concentrations of MBF were quantifiable for up to 168 h in both groups. The elimination half-life values of MBF were long (33.99 and 39.28 h for 2 and 4 mg/kg, respectively) with no significant differences between the groups. The average plasma protein binding of MBF was 30.85%. According to the surrogated PK/PD parameter (AUC0-24 -to-MIC ratio >100-125), the 2 and 4 mg/kg dosing rates should be effective for bacteria with MIC values lower than 0.125 μg/mL and 0.35 μg/mL, respectively.
Collapse
Affiliation(s)
- Mona Yalong
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| | - Kraisiri Khidkhan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Napasorn Phaochoosak
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Narongsak Chaiyabutr
- Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand
| | | | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
5
|
Poapolathep A, Jongkolpath O, Giorgi M, Klangkaew N, Phaochoosak N, Chomcheun T, Archawakulathep A, Poapolathep S. Disposition kinetics of meloxicam in green sea turtles (Chelonia mydas) after intravenous and intramuscular administrations. J Vet Pharmacol Ther 2024; 47:54-59. [PMID: 37715547 DOI: 10.1111/jvp.13406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2023] [Revised: 08/22/2023] [Accepted: 09/01/2023] [Indexed: 09/17/2023]
Abstract
The pharmacokinetics were described of meloxicam (MLX) in green sea turtles (Chelonia mydas), following a single intravenous (i.v.) and intramuscular (i.m.) administrations at one of two dosages of 0.1 or 0.2 mg/kg body weight (b.w.). The sample of 20 green sea turtles was divided into four groups (n = 5) using a randomization procedure according to a parallel study design. Blood samples were collected at pre-assigned times up to 168 h. MLX in the plasma was cleaned-up and quantified using a validated high-performance liquid chromatography method with UV detection. The concentration of MLX in the experimental green sea turtles with respect to time was pharmacokinetically analyzed using a non-compartment model. MLX plasma concentrations were quantifiable for up to 72 and 120 h after i.v. at dosages of 0.1 and 0.2 mg/kg b.w., respectively, whereas it was measurable for up to 168 h after i.m. administration at both dosages. The long elimination half-life value of MLX (28 h) obtained in green sea turtles after i.v. administration was consistent with the quite slow clearance rate for both dosages. The average maximum concentration (Cmax ) values of MLX were 1.05 μg/mL and 4.26 μg/mL at dosages of 0.1 and 0.2 mg/kg b.w., respectively, with their elimination half-life values being 37.26 h and 30.64 h, respectively, after i.m. administrations. The absolute i.m. bioavailability was approximately 110%. These results suggested that i.m. administration of MLX at a dosage of 0.2 mg/kg b.w. was likely to be effective for clinical use in green sea turtles (Chelonia mydas). However, further studies are needed to determine the pharmacodynamic properties and clinical efficacy of MLX for the treatment of inflammatory disease after single and multiple dosages.
Collapse
Affiliation(s)
- Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Oranee Jongkolpath
- Eastern Marine and Coastal Resources Research and Development Center, Rayong, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Italy
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Napasorn Phaochoosak
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Thanaphan Chomcheun
- Eastern Marine and Coastal Resources Research and Development Center, Rayong, Thailand
| | - Amornthep Archawakulathep
- Department of Veterinary Public Health, Faculty of Veterinary Medicine, Kasetsart University, Nakhon Pathom, Thailand
| | - Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
6
|
Abdel Aziz AA, Abdel Aziz ESA, Khairy MH, Fadel C, Giorgi M, Abdelaziz AS. The effect of butyric acid and nucleotides supplementation on broiler ( Gallus gallus domesticus) growth performance, immune status, intestinal histology, and serum parameters. Open Vet J 2024; 14:324-334. [PMID: 38633159 PMCID: PMC11018416 DOI: 10.5455/ovj.2024.v14.i1.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2023] [Accepted: 12/15/2023] [Indexed: 04/19/2024] Open
Abstract
Background Butyric acid and its derivatives support the immune system, lessen inflammation, and lessen oxidative stress in broilers in addition to preserving gut homeostasis and epithelial integrity. Broiler performance has also been demonstrated to rise with the addition of nucleotides to the diet. Aim The purpose of the study was to ascertain the effects of butyric acid and nucleotides added to feed on the overall performance, immunity, oxidant/antioxidant enzyme levels, intestinal histology, and hepatic functions of broilers. Methods Four experimental groups of thirty chickens, each were used in the present study. The groups were assigned as a control group that received normal diet without additives, butyrate (B) group received the diet supplemented with butyric acid (250 g/ton feed), nucleotides (N) group received the diet supplemented with nucleotides (200 g/ton feed), and the fourth group received the diet supplemented with a combination of butyrate and nucleotide (BN) (250 g/ton B feed, and 200 g/ton N feed, respectively). Necrotic enteritis was produced in ten birds from each group to assess the immune-modulatory effect of these supplements, antioxidant status, intestinal histology, and liver functions were measured in all experimental groups. Results The addition of butyric acid and nucleotides to feed enhanced body weight, growth performance, hepatic functions, and antioxidant capabilities. Histological sections of the gut from challenged or unchallenged (with necrotic enteritis) groups in the BN group showed considerable improvement, as shown by strong proliferation in intestinal crypts and villus enterocytes. Conclusion Nucleotides and butyric acid can be added to broiler feeding regimens to enhance growth and health.
Collapse
Affiliation(s)
- Ahmed A.M. Abdel Aziz
- Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt
| | - El-Sayed A. Abdel Aziz
- Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt
| | - Mohamed H. Khairy
- Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt
| | - Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| | - Ahmed S. Abdelaziz
- Department of Pharmacology, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt
| |
Collapse
|
7
|
Sartini I, Vercelli C, Lebkowska-Wieruszewska B, Lisowski A, Fadel C, Poapolathep A, Dessì F, Giorgi M. Pharmacokinetics and antibacterial activity of tiamulin after single and multiple oral administrations in geese. Vet Anim Sci 2023; 22:100317. [PMID: 37920697 PMCID: PMC10618762 DOI: 10.1016/j.vas.2023.100317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2023] Open
Abstract
Tiamulin is an antibiotic approved exclusively in veterinary medicine, active against G-positive bacteria as well as Mycoplasma spp. and Leptospirae spp. The study was aimed to establish its pharmacokinetics and to evaluate drug effects on resistance in cloacal flora in vivo in geese. Eight healthy geese underwent to a two-phase longitudinal study (60 mg/kg single oral administration vs 60 mg/kg/day for 4 days) with a two-week wash-out period. Blood samples and cloacal swabs were collected at pre-assigned times. Minimal inhibitory concentration (MIC) has been evaluated for each isolated bacterial species. The pharmacokinetic parameters that significantly differed between the groups were Cmax (p = 0.024), AUC0-t (p = 0.031), AUC0-inf (p = 0.038), t1/2kel (p = 0.021), Cl/F (p = 0.036), and Vd/F (p = 0.012). Tiamulin exhibited a slow to moderate terminal half-life (3.13 h single; 2.62 h multiple) and a rapid absorption (1 h single; 0.5 h multiple) in geese, with an accumulation ratio of 1.8 after multiple doses. An in-silico simulation of multiple dosing did not reflect the results of the in vivo multiple dosage study. In both treatments, the MIC values were very high demonstrating a resistance (> 64 μg/ml) against tiamulin that can be present prior the drug administration for some strains, or emerge shortly after the commencing of treatment for some others.
Collapse
Affiliation(s)
- Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Cristina Vercelli
- Department of Veterinary Sciences, University of Turin, Torino, Italy
| | | | - Andrzej Lisowski
- Department of Biology and Animal Breeding, University of Life Sciences, Lublin, Poland
| | - Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Filomena Dessì
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
- Department of Veterinary Sciences, University of Pisa, Via Livornese (lato monte), 56122, San Piero a Grado, Pisa, Italy
| |
Collapse
|
8
|
Kyriakopoulou A, Papaevangelou V, Argyropoulou M, Papathanasiou M, Xydis V, Giorgi M, Ntorkou A, Chlapoutaki C, Alexopoulou E. Fetal brain imaging provides valuable information in cCMV infected infants. J Matern Fetal Neonatal Med 2023; 36:2220564. [PMID: 37290964 DOI: 10.1080/14767058.2023.2220564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2022] [Revised: 05/01/2023] [Accepted: 05/23/2023] [Indexed: 06/10/2023]
Abstract
BACKGROUND Congenital CMV infection (cCMV) is the most common congenital infection with 10-15% of cases developing symptomatic disease. Early antiviral treatment is of essence when symptomatic disease is suspected. Recently, the use of neonatal imaging has been implicated as a prognostic tool for long term sequalae among asymptomatic newborns at high risk. Even though neonatal MRI is commonly used in neonatal symptomatic cCMV disease, it is less often used in asymptomatic newborns, mainly due to cost, access and difficulty to perform. We have therefore developed an interest in assessing the use of fetal imaging as an alternative. Our primary aim was to compare the fetal and neonatal MRIs in a small cohort 10 asymptomatic neonates with congenital CMV infection. METHODS We performed a single-center retrospective cohort study (case-series) on a convenience sample of children born from January 2014 to March 2021 with confirmed congenital CMV infection who had undergone both fetal and neonatal MRIs. We created a checklist of relevant cerebral abnormalities and asked 4 blinded radiologists to assess the MRIs (2 for each, namely fetal and neonatal) and then compared the findings between the fetal and neonatal imaging as well as the concordance in reporting of abnormalities within each category. FINDINGS Overall concordance between prenatal and postnatal scans was high (70%). When comparing the two blinded reports for each MRI, we found high levels of concordance: 90% concordance for fetal MRIs and 100% for neonatal MRIs. The most common abnormalities identified in both fetal and neonatal scans were "abnormal white matter hyperintensity" and "subependymal cysts." INTERPRETATION Even though this is a small descriptive study, it indicates that fetal MRI could potentially provide us with similar information as neonatal imaging. This study could form the basis for subsequent larger future studies.
Collapse
Affiliation(s)
- A Kyriakopoulou
- National and Kapodistrian University of Athens, Third Department of Paediatrics, Attikon General University Hospital, Athens, Greece
| | - V Papaevangelou
- National and Kapodistrian University of Athens, Third Department of Paediatrics, Attikon General University Hospital, Athens, Greece
| | - M Argyropoulou
- Department of Radiology Medical School, University of Ioannina, Ioannina, Greece
| | - M Papathanasiou
- School of Medicine, National and Kapodistrian University of Athens, 2nd Department of Radiology, General University Hospital Attikon, Athens, Greece
| | - V Xydis
- Department of Radiology Medical School, University of Ioannina, Ioannina, Greece
| | - M Giorgi
- National and Kapodistrian University of Athens, Third Department of Paediatrics, Attikon General University Hospital, Athens, Greece
| | - A Ntorkou
- Department of Paediatric Radiology, Robert Debré University Hospital, AP-HP, Paris, France
| | | | - E Alexopoulou
- School of Medicine, National and Kapodistrian University of Athens, 2nd Department of Radiology, General University Hospital Attikon, Athens, Greece
| |
Collapse
|
9
|
Fadel C, Łebkowska-Wieruszewska B, Bourdo K, Poapolathep A, Hassoun G, Giorgi M. Metronidazole pharmacokinetics in geese (Anser anser domesticus) after intravenous and oral administrations. J Vet Pharmacol Ther 2023. [PMID: 38032073 DOI: 10.1111/jvp.13421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Revised: 11/14/2023] [Accepted: 11/19/2023] [Indexed: 12/01/2023]
Abstract
Metronidazole (MTZ) is a 5-nitroimidazole anti-bacterial and anti-protozoal drug. In human and companion animal medicine, MTZ remains widely used due to its effectiveness against anaerobic bacteria and protozoa. In farm animals, however, MTZ is currently prohibited in several countries due to insufficient data on nitroimidazoles. The purpose of this study was to assess its pharmacokinetics (PK) in geese after single intravenous (IV) and oral (PO) administrations. Fifteen-month old healthy male geese (n = 8) were used. Geese were subjected to a two-phase, single-dose (10 mg/kg IV, 50 mg/kg PO), open, longitudinal study design with a two-week washout period between the IV and PO phases. Blood was drawn from the left wing vein to heparinized tubes at 0, 0.085 (for IV only), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 24, and 48 h. Plasma MTZ concentrations were measured using HPLC coupled to an UV detector, and the data were pharmacokinetically analyzed using PKanalix™ software with a non-compartmental approach. MTZ was still quantifiable and well above the LLOQ at 24 h after both routes of administration. Following IV administration, terminal elimination half-life, volume of distribution, and total clearance were 5.47 h, 767 mL/kg, and 96 mL/h/kg, respectively. For the PO route, the bioavailability was high (85%), and the mean peak plasma concentration was 60.27 μg/mL at 1 h. When parameters were normalized for the dose, there were no statistically significant differences for any of the PK parameters between the two routes of administration. The study shows that oral administration of MTZ seems to be promising in geese, although comprehensive research on its pharmacodynamics and multiple-dose studies are necessary before its adoption in geese can be further considered.
Collapse
Affiliation(s)
- Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Krzysztof Bourdo
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Faculty of Veterinary Medicine, Department of Pharmacology, Kasetsart University, Bangkok, Thailand
| | - Georges Hassoun
- Department of Environment and Natural Resources, Lebanese University, Beirut, Lebanon
| | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| |
Collapse
|
10
|
Fadel C, Łebkowska-Wieruszewska B, Zizzadoro C, Lisowski A, Poapolathep A, Giorgi M. Pharmacokinetics of robenacoxib following single intravenous, subcutaneous and oral administrations in Baladi goats (Capra hircus). J Vet Pharmacol Ther 2023; 46:385-392. [PMID: 37246240 DOI: 10.1111/jvp.13396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 04/19/2023] [Accepted: 05/02/2023] [Indexed: 05/30/2023]
Abstract
The purpose of this study was to assess the pharmacokinetics of robenacoxib (RX), a COX-2 selective non-steroidal anti-inflammatory drug, in goats after single intravenous (IV), subcutaneous (SC) and oral (PO) administrations. 5-month-old healthy female goats (n = 8) were used. The animals were subjected to a three-phase, two-dose (2 mg/kg IV, 4 mg/kg SC, PO) unblinded, parallel study design, with a four-month washout period between the IV and SC treatment, and a one-week period between the SC and PO treatment. Blood was drawn from the jugular vein in heparinized vacutainer tubes at 0, 0.085 (for IV only), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10 and 24 h. Plasma RX concentrations were measured using HPLC coupled to a UV multiple wavelength detector, and the data were pharmacokinetically analysed using ThothPro™ 4.3 software in a non-compartmental approach. Following IV administration, terminal elimination half-life, volume of distribution and total clearance were 0.32 h, 0.24 L/kg and 0.52 L/h/kg, respectively. For SC and PO, the mean peak plasma concentrations were 2.34 and 3.34 μg/mL at 1.50 and 0.50 h, respectively. The t1/2λz was significantly different between the IV and the extravascular (EV) administrations (0.32 h IV vs 1.37 h SC and 1.63 h PO), suggesting the occurrence of a flip-flop phenomenon. The significant difference in Vd values between IV (0.24 L/kg) and EV (0.95 L/kg SC and 1.71 L/kg; corrected for F %) routes might have also triggered the t1/2λz difference. The absolute average SC and PO bioavailability were high (98% and 91%, respectively). In conclusion, the IV administration of RX might not be suitable for goats, due to its short t1/2λz. The EV routes, however, appear to be convenient for the drug's occasional use.
Collapse
Affiliation(s)
- Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Claudia Zizzadoro
- Department of Veterinary Medicine, University of Bari, Valenzano (Bari), Italy
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Faculty of Veterinary Medicine, Department of Pharmacology, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| |
Collapse
|
11
|
Fadel C, Łebkowska-Wieruszewska B, Lisowski A, Laut S, Poapolathep A, Giorgi M. Disposition kinetics of robenacoxib following intravenous and oral administration in geese (Anser anser domesticus). J Vet Pharmacol Ther 2023; 46:413-420. [PMID: 37312265 DOI: 10.1111/jvp.13398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2023] [Revised: 05/24/2023] [Accepted: 06/01/2023] [Indexed: 06/15/2023]
Abstract
Robenacoxib (RX) is a veterinary cyclooxygenase-2 selective inhibitor drug. It has never been tested on birds and is only labelled for use in cats and dogs. The purpose of this study was to assess its pharmacokinetics in geese after single intravenous (IV) and oral (PO) administrations. Four-month healthy female geese (n = 8) were used. Geese were subjected to a two-phase, single-dose (2 mg/kg IV, 4 mg/kg PO), open, longitudinal study design with a four-month washout period between the IV and the PO phases. Blood was collected from the left wing vein to heparinized tubes at 0, 0.085 (for IV only), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, and 24 h. Plasma RX concentrations were measured using HPLC coupled to an UV detector, and the data were pharmacokinetically analysed using ThothPro™ 4.3 software in a non-compartmental approach. Following IV administration, terminal elimination half-life, volume of distribution, and total clearance were 0.35 h, 0.34 L/kg, and 0.68 L/h/kg, respectively. For the PO route, the mean peak plasma concentration was 6.78 μg/mL at 0.50 h. The t1/2λz was very short and significantly different between the IV and PO administrations (0.35 h IV vs. 0.99 h PO), suggesting the occurrence of a flip-flop phenomenon. The Cl values corrected for the F% were significantly different between IV and PO administrations. It might have been a consequence of the longitudinal study design and the altered physiological and environmental conditions after a 4-month washout period. The absolute oral F% computed with the AUC method surpassed 150%, but after normalizing it to t1/2λz, it was 46%. In conclusion, the administration of RX might not be suitable for geese, due to its short t1/2λz.
Collapse
Affiliation(s)
- Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Seavchou Laut
- Faculty of Veterinary Medicine, Department of Pharmacology, Kasetsart University, Bangkok, Thailand
| | - Amnart Poapolathep
- Faculty of Veterinary Medicine, Department of Pharmacology, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| |
Collapse
|
12
|
Habib N, Centini G, Klebanoff JS, Fernandes R, Giorgi M, Moawad GN, Bakar J. Pudendal Neuralgia: Two case reports with laparoscopic nerve decompression. Facts Views Vis Obgyn 2023; 15:181-187. [PMID: 37436058 PMCID: PMC10410660 DOI: 10.52054/fvvo.15.2.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/13/2023] Open
Abstract
Pudendal neuralgia (PN) is a rare and underestimated condition. The reported incidence by the International Pudendal Neuropathy Association is 1/100000. However, the actual rate may be significantly higher, with a propensity for women. It is most frequently caused by an entrapment of the nerve at the level of the sacrospinous and sacrotuberous ligament, also known as pudendal nerve entrapment syndrome. Due to the late diagnosis and inadequate management, pudendal nerve entrapment syndrome often leads to considerable reduction in the quality of life and high health care costs. The diagnosis is made using Nantes Criteria, in conjunction with the patient's clinical history and physical findings. Clinical examination with an accurate assessment of the territory of the neuropathic pain is mandatory to set the therapeutic strategy. The aim of the treatment is to control the symptoms and it usually starts with conservative approaches which include analgesics, anticonvulsants, and muscle relaxants. Surgical nerve decompression can be proposed after failure of conservative management. The laparoscopic approach is a feasible and appropriate technique to explore and decompress the pudendal nerve, and to rule out other pelvic conditions that can cause similar symptomatology. In this paper, the clinical history of two patients affected by compressive PN is reported. Both patients underwent laparoscopic pudendal neurolysis suggesting that the treatment for PN should be individualised and carried out by a multidisciplinary team. When conservative treatment fails, laparoscopic nerve exploration and decompression is an adequate option to propose and should be performed by a trained surgeon.
Collapse
|
13
|
Oster E, Čudina N, Pavasović H, Prevendar Crnić A, Božić F, Fadel C, Giorgi M. Intoxication of dogs and cats with common stimulating, hallucinogenic and dissociative recreational drugs. Vet Anim Sci 2023; 19:100288. [PMID: 36798946 PMCID: PMC9926018 DOI: 10.1016/j.vas.2023.100288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
Abstract
Pets can have accidental, intentional, or malicious exposure to illicit drugs. It is a growing concern over the last decade because there is an increase in usage of illicit drugs in humans and diagnosis is difficult. Owners are often not aware of exposure, or they are reluctant to admit possession of recreational drugs in the household due to potential legal consequences. In addition, illicit drugs sold on the black market are often adulterated with other substances resulting in non-specific clinical presentation and aggravation of symptoms. There are affordable onsite diagnostic tests on the market which could facilitate diagnosis of intoxication with illicit drugs, but they give a lot of false positive results due to low specificity of the tests. In this paper we gathered information about the most common recreational drugs such as amphetamines, methamphetamine, 3,4-methylenedioxy-methamphetamine (MDMA), phencyclidine (PCP), lysergic acid diethylamide (LSD), psilocybin mushrooms and cocaine in terms of toxicokinetic properties, mechanism of toxic action, clinical presentation and treatment in dogs and cats.
Collapse
Affiliation(s)
- Ena Oster
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Croatia
| | - Nikola Čudina
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Croatia
| | - Hrvoje Pavasović
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Croatia
| | - Andreja Prevendar Crnić
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Croatia
| | - Frane Božić
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Zagreb, Croatia
| | - Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Italy
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Italy,Corresponding author at: Department of Veterinary Sciences, University of Pisa, Pisa, Italy.
| |
Collapse
|
14
|
Laut S, Poapolathep S, Piasai O, Sommai S, Boonyuen N, Giorgi M, Zhang Z, Fink-Gremmels J, Poapolathep A. Storage Fungi and Mycotoxins Associated with Rice Samples Commercialized in Thailand. Foods 2023; 12:foods12030487. [PMID: 36766016 PMCID: PMC9914209 DOI: 10.3390/foods12030487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 01/12/2023] [Accepted: 01/18/2023] [Indexed: 01/24/2023] Open
Abstract
The study focused on the examination of the different fungal species isolated from commercial rice samples, applying conventional culture techniques, as well as different molecular and phylogenic analyses to confirm phenotypic identification. Additionally, the mycotoxin production and contamination were analyzed using validated liquid chromatography-tandem mass spectrometry (LC-MS/MS). In total, 40 rice samples were obtained covering rice berry, red jasmine rice, brown rice, germinated brown rice, and white rice. The blotting paper technique applied on the 5 different types of rice samples detected 4285 seed-borne fungal infections (26.8%) for 16,000 rice grains. Gross morphological data revealed that 19 fungal isolates belonged to the genera Penicillium/Talaromyces (18 of 90 isolates; 20%) and Aspergillus (72 of 90 isolates; 80%). To check their morphologies, molecular data (fungal sequence-based BLAST results and a phylogenetic tree of the combined ITS, BenA, CaM, and RPB2 datasets) confirmed the initial classification. The phylogenic analysis revealed that eight isolates belonged to P. citrinum and, additionally, one isolate each belonged to P. chermesinum, A. niger, A. fumigatus, and A. tubingensis. Furthermore, four isolates of T. pinophilus and one isolate of each taxon were identified as Talaromyces (T. radicus, T. purpureogenum, and T. islandicus). The results showed that A. niger and T. pinophilus were two commonly occurring fungal species in rice samples. After subculturing, ochratoxin A (OTA), generated by T. pinophilus code W3-04, was discovered using LC-MS/MS. In addition, the Fusarium toxin beauvericin was detected in one of the samples. Aflatoxin B1 or other mycotoxins, such as citrinin, trichothecenes, and fumonisins, were detected. These preliminary findings should provide valuable guidance for hazard analysis critical control point concepts used by commercial food suppliers, including the analysis of multiple mycotoxins. Based on the current findings, mycotoxin analyses should focus on A. niger toxins, including OTA and metabolites of T. pinophilus (recently considered a producer of emerging mycotoxins) to exclude health hazards related to the traditionally high consumption of rice by Thai people.
Collapse
Affiliation(s)
- Seavchou Laut
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand
| | - Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand
| | - Onuma Piasai
- Department of Plant Pathology, Faculty of Agriculture, Kasetsart University, Bangkok 10900, Thailand
| | - Sujinda Sommai
- Plant Microbe Interaction Research Team (APMT), National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand
| | - Nattawut Boonyuen
- Plant Microbe Interaction Research Team (APMT), National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand
| | - Mario Giorgi
- Department of Veterinary Science, University of Pisa, 56124 Pisa, Italy
| | - Zhaowei Zhang
- Oil Crops Research Institute of the Chinese Academy of Agricultural Sciences, Wuhan 430062, China
| | - Johanna Fink-Gremmels
- Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 Utrecht, The Netherlands
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand
- Correspondence: ; Tel.: +66-2-5797537
| |
Collapse
|
15
|
Fadel C, Giorgi M. Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses. Vet Anim Sci 2023; 19:100286. [PMID: 36684818 PMCID: PMC9852958 DOI: 10.1016/j.vas.2023.100286] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
According to in vitro and in vivo investigations, firocoxib (FX), a second-generation coxib, is a highly selective COX-2 inhibitor in horses. With a COX-1/COX-2 IC50 ratio of 643 in horses, FX spares the COX-1 inhibitory effects. It is approved for the treatment of musculoskeletal problems and lameness in horses and dogs with osteoarthritis (OA). For the treatment of OA in horses, both an injectable formulation for IV administration at a dose of 0.09 mg/kg for five days and an oral paste formulation at a dose of 0.1 mg/kg for 14 days are licensed. Numerous analytical methods were reported in the literature to quantify FX in biological fluids, using HPLC and LC-MS. FX presents remarkable pharmacokinetics and pharmacodynamics compared to other coxibs. It has an oral bioavailability of 80% or higher and is effectively absorbed by horses. Its volume of distribution is around 2 L/kg, and it is slowly eliminated. Due to the long elimination half-life (around 2 days), which allows a once daily dosing, a single 0.3 mg/kg loading dose has been recommended. This enables the establishment of steady-state drug concentrations within 24 h, making it appropriate for acute treatment as well. Its IC80 is equal to 103 ng/mL in whole blood and, with an EC50 of 27 ng/mL, it has the highest affinity for its receptor compared to the other commonly administered NSAIDs in horses.
Collapse
Affiliation(s)
- Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy,Department of Veterinary Sciences, University of Pisa, Pisa, Italy,Corresponding author.
| |
Collapse
|
16
|
Fadel C, Łebkowska‐Wieruszewska B, Sartini I, Lisowski A, Poapolathep A, Giorgi M. Robenacoxib pharmacokinetics in sheep following oral, subcutaneous, and intravenous administration. J Vet Pharmacol Ther 2022; 45:550-557. [PMID: 35899473 PMCID: PMC9796919 DOI: 10.1111/jvp.13089] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2022] [Revised: 07/07/2022] [Accepted: 07/17/2022] [Indexed: 01/07/2023]
Abstract
The aim of this study was to evaluate the pharmacokinetics (PK) of robenacoxib (RX), a COX-2 selective non-steroidal anti-inflammatory drug, in sheep after single subcutaneous (SC), oral (PO), and intravenous (IV) administration. Five healthy female sheep underwent a three-phase parallel study design with a washout period of 4 weeks, in which sheep received a 4 mg/kg SC dose in phase 1, a 4 mg/kg PO administration in phase 2, and a 2 mg/kg IV administration in phase 3. Plasma RX concentrations were measured over a 48 h period for each treatment using HPLC coupled to a UV multiple wavelength detector, and the PK parameters were estimated using a non-compartmental method. Following IV administration, terminal elimination half-life, volume of distribution at steady state, and total clearance were 2.64 h, 0.077 L/kg, and 0.056 L/h kg, respectively. The mean peak plasma concentrations following SC and PO administrations were 7.04 and 3.01 μg/mL, respectively. The mean bioavailability following SC and PO administrations were 45.98% and 16.58%, respectively. The SC route may be proposed for use in sheep. However, the multi-dose and pharmacodynamic studies are necessary to establish more accurately its safety and efficacy in sheep.
Collapse
Affiliation(s)
- Charbel Fadel
- Department of Veterinary MedicineUniversity of SassariSassariItaly
| | | | - Irene Sartini
- Department of Veterinary SciencesUniversity of PisaPisaItaly
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity ConservationUniversity of Life SciencesLublinPoland
| | - Amnart Poapolathep
- Faculty of Veterinary Medicine, Department of PharmacologyKasetsart UniversityBangkokThailand
| | - Mario Giorgi
- Department of Veterinary MedicineUniversity of SassariSassariItaly,Department of Veterinary SciencesUniversity of PisaPisaItaly
| |
Collapse
|
17
|
Khidkhan K, Poapolathep S, Kulprasertsri S, Sukkheewan R, Khunlert P, Giorgi M, Poapolathep A. Comparative in vitro biotransformation of fipronil in domestic poultry using liver microsome. J Vet Sci 2022; 23:e82. [PMID: 36259101 PMCID: PMC9715393 DOI: 10.4142/jvs.22178] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Revised: 08/21/2022] [Accepted: 09/01/2022] [Indexed: 12/15/2022] Open
Abstract
Domestic poultry are among the non-target species of exposure to fipronil, but limited information is available on the metabolic effects of fipronil exposure in avian. We investigated the comparative capacity of in vitro biotransformation of fipronil among chicken, duck, quail, goose, and rat. Interspecies differences in kinetic parameters were observed; the clearance rate calculations (Vmax/Km) indicated that chicken and duck are more efficient in the cytochrome P450-mediated metabolism of fipronil to sulfone than quail, goose and rat. The lower hepatic clearance of fipronil in quail, goose and rat, suggested that fipronil sulfone may serve as a biomarker to indicate fipronil exposure in these species.
Collapse
Affiliation(s)
- Kraisiri Khidkhan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand
| | - Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand
| | - Sittinee Kulprasertsri
- Department of Farm Resources and Production Medicine, Faculty of Veterinary Medicine, Kasetsart University, Kamphaeng Saen Campus, Nakhon Pathom 73140, Thailand
| | - Rattapong Sukkheewan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand
| | - Paphatsara Khunlert
- Agricultural Toxic Substance Research Group, Agricultural Production Sciences Research and Development Division, Department of Agriculture, Ministry of Agriculture and Cooperatives, Bangkok 10900, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Via Livornese (latomonte), San Piero a Grado, Italy
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand
| |
Collapse
|
18
|
Youssefi MR, Khabbazian FG, Navidi N, Yazdani Rostam MM, Giorgi M, Abouhosseini Tabari M. Pharmacokinetics and therapeutic efficacies of fenbendazole in comparison with levamisole in helminth-infected Caspian turtles (Mauremys caspica). J Vet Pharmacol Ther 2022; 46:170-176. [PMID: 36065517 DOI: 10.1111/jvp.13094] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 08/19/2022] [Accepted: 08/23/2022] [Indexed: 11/27/2022]
Abstract
The pharmacokinetics and bioavailability of fenbendazole and levamisole were determined in Caspian turtles after a single intravenous (i.v.) and subcutaneous (s.c.) administration. Thirty turtles diagnosed as naturally infected with Serpinema microcephalus and Falcaustra armenica nematodes received fenbendazole (50 mg/kg) or levamisole (10 mg/kg) by i.v. and s.c. administrations. Blood samples were collected at time 0, 0.125, 0.25, 0.5, 1, 2, 4, 8, 12, 24, and 48 h after drug administration. Plasma drug concentrations were determined by a validated high-performance liquid chromatography method. Data were analyzed by noncompartmental methods. The mean elimination half-life of levamisole was 5.16 h and 12.03 h for i.v. and s.c. routes, respectively, and for fenbendazole, the mean elimination half-life was 25.38 h (i.v.) and 29.77 h (s.c.). The total clearance and volume of distribution at steady-state for levamisole and fenbendazole following i.v. administration were 0.22, 0.44 ml/g/h, and 1.06 and 7.35 ml/g, respectively. For the s.c. route, the peak plasma concentration of levamisole and fenbendazole was 10.53 and 5.24 μg/mL, respectively. The s.c. bioavailability of levamisole and fenbendazole was complete. Considering high anthelmintic efficacy and bioavailability after s.c. administration of levamisole and fenbendazole, and the absence of adverse effects, this route of administration is an easy and efficacious way of treating nematodes in Caspian turtles.
Collapse
Affiliation(s)
- Mohammad Reza Youssefi
- Department of Veterinary Parasitology, Babol Branch, Islamic Azad University, Babol, Iran
| | | | - Niki Navidi
- Young Researchers and Elite Club, Sanandaj Branch, Islamic Azad University, Sanandaj, Iran
| | - Mohammad Mehdi Yazdani Rostam
- Resident of Small Animal Internal Medicine, Faculty of Veterinary Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| | | |
Collapse
|
19
|
Giorgi M, Berchadsky Y. CRISTAL-ITE: a single-crystal X-ray diffractometer scale model for scientific dissemination. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322089793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
20
|
Sartini I, Łebkowska-Wieruszewska B, Krupa M, Lisowski A, Poapolathep A, Giorgi M. Pharmacokinetics of ivermectin after oral and intravenous administration in Biłgorajska geese ( Anser anser domesticus). N Z Vet J 2022; 70:313-318. [DOI: 10.1080/00480169.2022.2104398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- I Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - B Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - M Krupa
- Mascotes Veterinary Practice, Komorniki, Poland
| | - A Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - A Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - M Giorgi
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| |
Collapse
|
21
|
Sukkheewan R, Poapolathep A, Giorgi M, Klangkaew N, Phaochoosak N, Wongwaipairoj T, Udomkusonsri P, Chaiyabutr N, Poapolathep S. Pharmacokinetic characteristics of azithromycin in freshwater crocodiles (Crocodylus siamensis) after intramuscular administration at three different dosages. J Vet Pharmacol Ther 2022; 45:501-507. [PMID: 35717656 DOI: 10.1111/jvp.13080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2022] [Revised: 06/07/2022] [Accepted: 06/08/2022] [Indexed: 11/30/2022]
Abstract
The study evaluated the pharmacokinetic features of azithromycin (AZM) in 15 freshwater crocodiles (Crocodylus siamensis) in Thailand. The crocodiles were administered a single intramuscular (i.m.) injection of AZM at three different dosages of 2.5, 5, and 10 mg/kg body weight (b.w.). Blood samples were collected at pre-assigned times up to 168 h. The plasma concentrations of AZM were measured using a validated liquid chromatography-tandem mass spectrometry method. The plasma concentration of AZM were quantifiable for up to 168 h after i.m. administration at the three different dosages. A non-compartmental model was used to fit the plasma concentration of AZM versus the time curve for each crocodile. The elimination half-life values of AZM were 33.70, 38.11, and 34.80 h following i.m. injection after dosages of 2.5, 5, and 10 mg/kg b.w., respectively. There were no significant differences among groups. The results indicated that the overall rate of elimination of AZM in freshwater crocodiles was relatively slow. The maximum concentration and area under the curve from zero to the last values of AZM increased in a dose-dependent fashion. The average binding percentage of AZM to plasma protein was 48.66%. Based on the pharmacokinetic data, the susceptibility break-point and the surrogate PK-PD index (T > MIC), the intramuscular administration of AZM at a dose of 10 mg/kg b.w. might be appropriate for the treatment of susceptible bacterial infections (MIC < 4 μg/ml) in freshwater crocodiles.
Collapse
Affiliation(s)
- Rattapong Sukkheewan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Italy
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Napasorn Phaochoosak
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | | | - Pareeya Udomkusonsri
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Narongsak Chaiyabutr
- Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand
| | - Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
22
|
Sartini I, Giorgi M. Veterinary pharmacology: A world almost unexplored with huge potential. Vet Anim Sci 2022; 16:100251. [PMID: 35462876 PMCID: PMC9020083 DOI: 10.1016/j.vas.2022.100251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Affiliation(s)
- Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Via Vienna 2, Sassari 07010, Italy
| | - Mario Giorgi
- Department of Veterinary Medicine, University of Sassari, Via Vienna 2, Sassari 07010, Italy
- Department of Veterinary Sciences, University of Pisa, Via Livornese (lato monte), S. Piero a Grado, Pisa 56121, Italy
- Corresponding author at: Department of Veterinary Sciences, University of Pisa, Via Livornese (lato monte), S. Piero a Grado, Pisa 56121, Italy.
| |
Collapse
|
23
|
Poapolathep S, Klangkaew N, Wongwaipairoj T, Chaiyabutr N, Giorgi M, Poapolathep A. Pharmacokinetics of danofloxacin in freshwater crocodiles (Crocodylus siamensis) after intramuscular injection. J Vet Pharmacol Ther 2022; 45:352-357. [PMID: 35582881 DOI: 10.1111/jvp.13072] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 04/21/2022] [Accepted: 05/05/2022] [Indexed: 11/28/2022]
Abstract
The present study evaluated the pharmacokinetic profiles of danofloxacin (DNX) in freshwater crocodiles (Crocodylus siamensis), following single intramuscular (i.m.) administrations at two different dosages of 6 and 12 mg/kg body weight (b.w.). Blood samples were collected at assigned times up to 168 h. DNX in the harvested crocodile plasma was extracted using liquid-liquid extraction and analyzed using a validated high-performance liquid chromatography method equipped with fluorescence detection. The pharmacokinetic analysis was performed using a non-compartmental approach. DNX in plasma was quantifiable from 5 min to 168 h after i.m. administration at the two dosages in freshwater crocodiles. The area under the curve (AUC) and maximum concentration (Cmax ) values increased in a dose-dependent fashion. Long elimination half-life (48.18 and 67.29 h) and low clearance (0.024 and 0.020 ml/g h) were obtained in the high- and low-dose groups, respectively. According to the pharmacokinetic-pharmacodynamic surrogate (AUC0-24h /MIC > 125), i.m. single administration of DNX at a dosage of 6 mg/kg b.w. is predicted to have antibacterial success for disease caused by bacteria with MIC < 0.04 μg/ml in the freshwater crocodile, C. siamensis.
Collapse
Affiliation(s)
- Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | | | - Narongsak Chaiyabutr
- Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Via Livornese (latomonte), San Piero a Grado, Italy
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
24
|
Levis M, Botto B, Andreis A, Gastino A, Blasi L, Bartoncini S, Giorgi M, Fava A, Cavallo F, Ferrero S, Boccomini C, Orsucci L, Ricardi U. OC-0293 Early detection of chemo and RT-related heart toxicity in lymphoma patients: The CARDIOCARE Project. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02551-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
25
|
Wanmad W, Chomcheun T, Jongkolpath O, Klangkaew N, Phaochoosak N, Sukkheewan R, Laovechprasit W, Khidkhan K, Giorgi M, Poapolathep A, Poapolathep S. Pharmacokinetic characteristics of danofloxacin in green sea (Chelonia mydas) and hawksbill sea (Eretmochelys imbricata) turtles. J Vet Pharmacol Ther 2022; 45:402-408. [PMID: 35332549 DOI: 10.1111/jvp.13054] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Revised: 03/08/2022] [Accepted: 03/15/2022] [Indexed: 11/28/2022]
Abstract
To date, the number of green sea and hawksbill sea turtles is in decline due to environmental, anthropogenic, and pathological factors. The present study described the pharmacokinetic characteristics of danofloxacin (DNX) in green sea and hawksbill sea turtles, following single intravenous (i.v.) and intramuscular (i.m.) administrations at single dosages of 6 mg/kg body weight (b.w.). Blood samples were collected at assigned times up to 168 h. DNX in the harvested plasma was cleaned up using liquid-liquid extraction and analyzed using a validated high-performance liquid chromatography method with fluorescence detection. The pharmacokinetic analysis was performed using a non-compartmental approach. DNX was quantifiable from 5 min to 168 h after i.v. and i.m. administrations at an identical dosage in both turtle types. No statistical differences were found in the pharmacokinetic parameters between green sea and hawksbill sea turtles. The long elimination half-life value of DNX obtained in green sea (35 h) and hawksbill sea (30.21 h) turtles was consistent with the quite large volume of distribution and the slow clearance rate. The high values of absolute bioavailability (87%-94%) should be advantageous for clinical use of DNX in sea turtles. According to the pharmacokinetic-pharmacodynamic surrogate (AUC0-24 /MIC > 125), DNX is predicted to have antibacterial success for disease caused by bacteria with MIC < 0.04 µg/ml.
Collapse
Affiliation(s)
- Wipasitnee Wanmad
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Thanaphan Chomcheun
- Eastern Marine and Coastal Resources Research and Development Center, Rayong, Thailand
| | - Oranee Jongkolpath
- Eastern Marine and Coastal Resources Research and Development Center, Rayong, Thailand
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Napasorn Phaochoosak
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Rattapong Sukkheewan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | | | - Kraisiri Khidkhan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Italy
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
26
|
Sartini I, Łebkowska-Wieruszewska B, Gbylik-Sikorska M, Pietruk K, Krawczyk A, Gajda A, Lisowski A, Poapolathep A, Giorgi M. Acetaminophen pharmacokinetics in geese. J Am Vet Med Assoc 2022; 260:1-8. [PMID: 35333747 DOI: 10.2460/javma.21.05.0250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate the pharmacokinetics of acetaminophen (APAP) after single-dose IV and PO in the goose; to quantify APAP and its main metabolites in goose muscle, heart, lung, liver, and kidney; and to perform a histopathologic evaluation of goose stomach, duodenum, liver, and kidney tissues for potential signs of toxicity. ANIMALS 24 geese. PROCEDURES Geese were randomly divided into 3 groups (n = 8). Group I received APAP (10 mg/kg) IV, and groups II and III received the same dose PO. Groups I and II were used for the pharmacokinetic assessment, and group III was used for the residue analysis and histopathologic evaluation. APAP and its metabolites were quantified in plasma and tissues by ultra-high-performance liquid chromatography-tandem mass spectrometry, and the pharmacokinetic analysis was performed using a noncompartmental approach. RESULTS APAP plasma concentrations were lower than those of the metabolites in similar selected time points after both treatments. After IV treatment, the APAP area under the curve value was statistically higher than that after PO administration, resulting in an oral bioavailability of 46%. In contrast, the area under the curve of the metabolites following PO administration was statistically higher than those found after IV administration. Tissue residues of APAP were highest in the liver, with an accumulation index > 1. Fatty degeneration of hepatocytes was observed 24 hours after administration of APAP. CLINICAL RELEVANCE In geese, treatment by PO administration of APAP shows incomplete absorption and a slight accumulation in lung and liver. Tissue alterations occurred in the liver at 24 hours, while no signs of toxicity were found in the other tested organs.
Collapse
Affiliation(s)
- Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | | | - Konrad Pietruk
- Department of Pharmacology and Toxicology, National Veterinary Research Institute, Puławy, Poland
| | - Aleksandra Krawczyk
- Department of Animal Anatomy and Histology, University of Life Sciences, Lublin, Poland
| | - Anna Gajda
- Department of Pharmacology and Toxicology, National Veterinary Research Institute, Puławy, Poland
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy.,School of veterinary Sciences, Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| |
Collapse
|
27
|
Fadel C, Sartini I, Giorgi M, Giorgi M. Gabapentin in Cattle: A Pharmacology Snapshot. American Journal of Animal and Veterinary Sciences 2022; 17:187-197. [DOI: 10.3844/ajavsp.2022.187.197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
28
|
Sartini I, Łebkowska-Wieruszewska B, Fadel C, Lisowski A, Poapolathep A, Giorgi M. Single and multiple oral amoxicillin treatment in geese: a pharmacokinetic evaluation. Br Poult Sci 2022; 63:493-498. [PMID: 35118922 DOI: 10.1080/00071668.2022.2036699] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
Although amoxicillin has broad-spectrum antibiotic activity and is extensive used in poultry, its use has never been investigated in geese. This study aimed to evaluate the pharmacokinetics of amoxicillin after a single and multiple oral doses in geese. A total of 20 geese were enrolled in this study and randomly pooled in two groups (n=10). In group I, animals were treated with a single oral 20 mg/kg dose of amoxicillin, while group II were administered multiple doses (20 mg/kg/day for 4 days). Concentrations of amoxicillin in plasma were analyzed using a validated HPLC-UV method and drug plasma concentrations were modeled for each subject using a non-compartmental approach. Amoxicillin showed rapid absorption after a single dose treatment, with an elimination half-life of approximately 1 h. Cmax, Tmax and AUC values differed statistically between groups I and II (after the first dose administered). A large variability was observed in the pharmacokinetic profiles and drug accumulation may occur after the multiple administration. No accumulation in plasma was predicted from an in-silico simulation performed using the same multiple dosage schedule. The in-silico simulation does not seem to accurately predict in-field conditions.
Collapse
Affiliation(s)
- Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Charbel Fadel
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy.,Department of Veterinary Medicine, PhD School of Veterinary Sciences, Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| |
Collapse
|
29
|
Barril G, Alvarez G, Giorgi M, Nuñez A, Pérez ÁN. Differences in the extracellular body water/total body water (ebw/tbw) in hemodialysis and chronic kidney disease patients. Relationship with nutritional parameters. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Poapolathep S, Giorgi M, Klangkaew N, Khidkhan K, Chaiyabutr N, Wongwaipairoj T, Poapolathep A. Pharmacokinetic profiles of clarithromycin in freshwater crocodiles (Crocodylus siamensis). J Vet Pharmacol Ther 2021; 45:147-152. [PMID: 34845734 DOI: 10.1111/jvp.13034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2021] [Revised: 11/13/2021] [Accepted: 11/17/2021] [Indexed: 12/26/2022]
Abstract
Clarithromycin (CLA) is a new β-lactamase-resistant macrolide antibiotic with potent activity against gram-positive and some gram-negative bacteria. To the authors' best knowledge, limited pharmacokinetic information to establish suitable therapeutic plans is available for freshwater crocodiles. To assess the prudent use of antibiotic in reptiles, this study was conducted to explore the pharmacokinetic characteristics of CLA in the freshwater crocodile, Crocodylus siamensis, following either single intravenous (i.v.) or intramuscular (i.m.) administration at a dosage of 2.5 mg/kg body weight (b.w.). Blood samples were collected at assigned times up to 168 h. CLA plasma samples were cleaned up using liquid-liquid extraction, and analysed by a validated liquid chromatography tandem-mass spectrometry (LC-MS/MS). CLA was quantifiable from 5 min to 72 h after i.v. administration, whereas it was detectable for 168 after i.m. administration at an identical dose rate. A non-compartmental model was used to fit the plasma concentration of CLA versus time curve for each crocodile. The t1/2λz value, similar for both routes (20 h), indicated that the overall rate of elimination of CLA in crocodiles is relatively slow. The average i.m. F% was complete. The protein plasma bound was found to be about 30%. CLA is a time-dependent antibiotic, and the T > MIC is the best PK/PD predictor for its efficacy. The CLA dosage of 2.5 mg/kg appeared to produce an appropriate value of the PK-PD surrogate that predicts antibacterial success for disease caused by susceptible bacteria.
Collapse
Affiliation(s)
- Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Italy
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Kraisiri Khidkhan
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Narongsak Chaiyabutr
- Department of Physiology, Faculty of Veterinary Science, Chulalongkorn, University, Bangkok, Thailand
| | | | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| |
Collapse
|
31
|
Leite AMM, Ronga MG, Giorgi M, Ristic Y, Perrot Y, Trompier F, Prezado Y, Créhange G, De Marzi L. Secondary neutron dose contribution from pencil beam scanning, scattered and spatially fractionated proton therapy. Phys Med Biol 2021; 66. [PMID: 34673555 DOI: 10.1088/1361-6560/ac3209] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Accepted: 10/21/2021] [Indexed: 11/11/2022]
Abstract
The Orsay Proton therapy Center (ICPO) has a long history of intracranial radiotherapy using both double scattering (DS) and pencil beam scanning (PBS) techniques, and is actively investigating a promising modality of spatially fractionated radiotherapy using proton minibeams (pMBRT). This work provides a comprehensive comparison of the organ-specific secondary neutron dose due to each of these treatment modalities, assessed using Monte Carlo (MC) algorithms and measurements. A MC model of a universal nozzle was benchmarked by comparing the neutron ambient dose equivalent,H*(10), in the gantry room with measurements obtained using a WENDI-II counter. The secondary neutron dose was evaluated for clinically relevant intracranial treatments of patients of different ages, in which secondary neutron doses were scored in anthropomorphic phantoms merged with the patients' images. The MC calculatedH*(10) values showed a reasonable agreement with the measurements and followed the expected tendency, in which PBS yields the lowest dose, followed by pMBRT and DS. Our results for intracranial treatments show that pMBRT yielded a higher secondary neutron dose for organs closer to the target volume, while organs situated furthest from the target volume received a greater quantity of neutrons from the passive scattering beam line. To the best of our knowledge, this is the first study to compare MC secondary neutron dose estimates in clinical treatments between these various proton therapy modalities and to realistically quantify the secondary neutron dose contribution of clinical pMBRT treatments. The method established in this study will enable epidemiological studies of the long-term effects of intracranial treatments at ICPO, notably radiation-induced second malignancies.
Collapse
Affiliation(s)
- A M M Leite
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France.,Institut Curie, PSL Research University, University Paris Saclay, Inserm U 1021- CNRS UMR 3347, F-91898 Orsay, France
| | - M G Ronga
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France
| | - M Giorgi
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France
| | - Y Ristic
- Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie, Laboratoire de Dosimétrie des Rayonnements Ionisants, F-92262 Fontenay-aux-Roses Cedex, France
| | - Y Perrot
- Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie, Laboratoire de Dosimétrie des Rayonnements Ionisants, F-92262 Fontenay-aux-Roses Cedex, France
| | - F Trompier
- Institut de Radioprotection et de Sûreté Nucléaire, Service de Dosimétrie, Laboratoire de Dosimétrie des Rayonnements Ionisants, F-92262 Fontenay-aux-Roses Cedex, France
| | - Y Prezado
- Institut Curie, PSL Research University, University Paris Saclay, Inserm U 1021- CNRS UMR 3347, F-91898 Orsay, France
| | - G Créhange
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France
| | - L De Marzi
- Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, F-91898 Orsay, France.,Institut Curie, PSL Research University, University Paris Saclay, Inserm LITO, F-91898 Orsay, France
| |
Collapse
|
32
|
Poapolathep S, Klangkaew N, Zhang Z, Giorgi M, Logrieco AF, Poapolathep A. Simultaneous Determination of Ergot Alkaloids in Swine and Dairy Feeds Using Ultra High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Toxins (Basel) 2021; 13:724. [PMID: 34679017 PMCID: PMC8540808 DOI: 10.3390/toxins13100724] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 10/01/2021] [Accepted: 10/09/2021] [Indexed: 11/29/2022] Open
Abstract
Ergot alkaloids (EAs) are mycotoxins mainly produced by the fungus Claviceps purpurea. EAs are known to affect the nervous system and to be vasoconstrictors in humans and animals. This work presents recent advances in swine and dairy feeds regarding 11 major EAs, namely ergometrine, ergosine, ergotamine, ergocornine, ergocryptine, ergocristine, ergosinine, ergotaminine, ergocorninine, ergocryptinine, and ergocristinine. A reliable, sensitive, and accurate multiple mycotoxin method, based on extraction with a Mycosep 150 multifunctional column prior to analysis using UHPLC-MS/MS, was validated using samples of swine feed (100) and dairy feed (100) for the 11 targeted EAs. Based on the obtained validation results, this method showed good performance recovery and inter-day and intra-day precision that are in accordance with standard criteria to ensure reliable occurrence data on EA contaminants. More than 49% of the swine feed samples were contaminated with EAs, especially ergocryptine(-ine) (40%) and ergosine (-ine) and ergotamine (-ine) (37%). However, many of the 11 EAs were not detectable in any swine feed samples. In addition, there were contaminated (positive) dairy feed samples, especially for ergocryptine (-ine) (50%), ergosine (-ine) (48%), ergotamine (-ine), and ergocristine (-ine) (49%). The mycotoxin levels in the feed samples in this study almost complied with the European Union regulations.
Collapse
Affiliation(s)
- Saranya Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand; (S.P.); (N.K.)
| | - Narumol Klangkaew
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand; (S.P.); (N.K.)
| | - Zhaowei Zhang
- Oil Crops Research Institute of the Chinese Academy of Agricultural Sciences, Wuhan 430062, China;
| | - Mario Giorgi
- Department of Veterinary Science, University of Pisa, 56122 Pisa, Italy;
| | | | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand; (S.P.); (N.K.)
- Center of Excellence on Agricultural Biotechnology (AG-BIO/MHESI), Bangkok 10900, Thailand
| |
Collapse
|
33
|
Aliberti R, Ambrosino F, Ammendola R, Angelucci B, Antonelli A, Anzivino G, Arcidiacono R, Bache T, Baeva A, Baigarashev D, Barbanera M, Bernhard J, Biagioni A, Bician L, Biino C, Bizzeti A, Blazek T, Bloch-Devaux B, Bonaiuto V, Boretto M, Bragadireanu AM, Britton D, Brizioli F, Brunetti MB, Bryman D, Bucci F, Capussela T, Carmignani J, Ceccucci A, Cenci P, Cerny V, Cerri C, Checcucci B, Conovaloff A, Cooper P, Cortina Gil E, Corvino M, Costantini F, Cotta Ramusino A, Coward D, D'Agostini G, Dainton JB, Dalpiaz P, Danielsson H, De Simone N, Di Filippo D, Di Lella L, Doble N, Duk V, Duval F, Döbrich B, Emelyanov D, Engelfried J, Enik T, Estrada-Tristan N, Falaleev V, Fantechi R, Fascianelli V, Federici L, Fedotov S, Filippi A, Fiorini M, Fry JR, Fu J, Fucci A, Fulton L, Gamberini E, Gatignon L, Georgiev G, Ghinescu SA, Gianoli A, Giorgi M, Giudici S, Gonnella F, Goudzovski E, Graham C, Guida R, Gushchin E, Hahn F, Heath H, Henshaw J, Holzer EB, Husek T, Hutanu OE, Hutchcroft D, Iacobuzio L, Iacopini E, Imbergamo E, Jenninger B, Jerhot J, Jones RWL, Kampf K, Kekelidze V, Kholodenko S, Khoriauli G, Khotyantsev A, Kleimenova A, Korotkova A, Koval M, Kozhuharov V, Kucerova Z, Kudenko Y, Kunze J, Kurochka V, Kurshetsov V, Lamanna G, Lanfranchi G, Lari E, Latino G, Laycock P, Lazzeroni C, Lehmann Miotto G, Lenti M, Leonardi E, Lichard P, Litov L, Lollini R, Lomidze D, Lonardo A, Lubrano P, Lupi M, Lurkin N, Madigozhin D, Mannelli I, Mapelli A, Marchetto F, Marchevski R, Martellotti S, Massarotti P, Massri K, Maurice E, Medvedeva M, Mefodev A, Menichetti E, Migliore E, Minucci E, Mirra M, Misheva M, Molokanova N, Moulson M, Movchan S, Napolitano M, Neri I, Newson F, Norton A, Noy M, Numao T, Obraztsov V, Ostankov A, Padolski S, Page R, Palladino V, Parenti A, Parkinson C, Pedreschi E, Pepe M, Perrin-Terrin M, Peruzzo L, Petrov P, Petrov Y, Petrucci F, Piandani R, Piccini M, Pinzino J, Polenkevich I, Pontisso L, Potrebenikov Y, Protopopescu D, Raggi M, Romano A, Rubin P, Ruggiero G, Ryjov V, Salamon A, Santoni C, Saracino G, Sargeni F, Schuchmann S, Semenov V, Sergi A, Shaikhiev A, Shkarovskiy S, Soldi D, Sozzi M, Spadaro T, Spinella F, Sturgess A, Sugonyaev V, Swallow J, Trilov S, Valente P, Velghe B, Venditti S, Vicini P, Volpe R, Vormstein M, Wahl H, Wanke R, Wrona B, Yushchenko O, Zamkovsky M, Zinchenko A. Search for Lepton Number and Flavor Violation in K^{+} and π^{0} Decays. Phys Rev Lett 2021; 127:131802. [PMID: 34623867 DOI: 10.1103/physrevlett.127.131802] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Accepted: 07/22/2021] [Indexed: 06/13/2023]
Abstract
Searches for the lepton number violating K^{+}→π^{-}μ^{+}e^{+} decay and the lepton flavor violating K^{+}→π^{+}μ^{-}e^{+} and π^{0}→μ^{-}e^{+} decays are reported using data collected by the NA62 experiment at CERN in 2017-2018. No evidence for these decays is found and upper limits of the branching ratios are obtained at 90% confidence level: B(K^{+}→π^{-}μ^{+}e^{+})<4.2×10^{-11}, B(K^{+}→π^{+}μ^{-}e^{+})<6.6×10^{-11} and B(π^{0}→μ^{-}e^{+})<3.2×10^{-10}. These results improve by 1 order of magnitude over previous results for these decay modes.
Collapse
Affiliation(s)
- R Aliberti
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - F Ambrosino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - R Ammendola
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - B Angelucci
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - A Antonelli
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - G Anzivino
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - R Arcidiacono
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - T Bache
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Baeva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Baigarashev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Barbanera
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Bernhard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Biagioni
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - L Bician
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Biino
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A Bizzeti
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Blazek
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - B Bloch-Devaux
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - V Bonaiuto
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - M Boretto
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - A M Bragadireanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Britton
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - F Brizioli
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M B Brunetti
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Bryman
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - F Bucci
- INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - T Capussela
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - J Carmignani
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - A Ceccucci
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Cenci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - V Cerny
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - C Cerri
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - B Checcucci
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - A Conovaloff
- George Mason University, Fairfax, Virginia 22030, USA
| | - P Cooper
- George Mason University, Fairfax, Virginia 22030, USA
| | - E Cortina Gil
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Corvino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Costantini
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | | | - D Coward
- George Mason University, Fairfax, Virginia 22030, USA
| | - G D'Agostini
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - J B Dainton
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - P Dalpiaz
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - H Danielsson
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - N De Simone
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Di Filippo
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - L Di Lella
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - N Doble
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Duk
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - F Duval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - B Döbrich
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - D Emelyanov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - J Engelfried
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - T Enik
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Estrada-Tristan
- Instituto de Física, Universidad Autónoma de San Luis Potosí, 78240 San Luis Potosí, Mexico
| | - V Falaleev
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Fantechi
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - V Fascianelli
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - L Federici
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Fedotov
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Filippi
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Fiorini
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - J R Fry
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - J Fu
- University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada
| | - A Fucci
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - L Fulton
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - E Gamberini
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Gatignon
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - G Georgiev
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S A Ghinescu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - A Gianoli
- INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Giorgi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - S Giudici
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - F Gonnella
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Goudzovski
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - C Graham
- University of Glasgow, Glasgow G12 8QQ, United Kingdom
| | - R Guida
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Gushchin
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - F Hahn
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - H Heath
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - J Henshaw
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E B Holzer
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Husek
- Charles University, 116 36 Prague 1, Czech Republic
| | - O E Hutanu
- Horia Hulubei National Institute of Physics for R&D in Physics and Nuclear Engineering, 077125 Bucharest-Magurele, Romania
| | - D Hutchcroft
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - L Iacobuzio
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Iacopini
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Imbergamo
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - B Jenninger
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - J Jerhot
- Charles University, 116 36 Prague 1, Czech Republic
| | - R W L Jones
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - K Kampf
- Charles University, 116 36 Prague 1, Czech Republic
| | - V Kekelidze
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - S Kholodenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Khoriauli
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Khotyantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Kleimenova
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - A Korotkova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Koval
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Kozhuharov
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - Z Kucerova
- Faculty of Mathematics, Physics and Informatics, Comenius University, 842 48 Bratislava, Slovakia
| | - Y Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - J Kunze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - V Kurochka
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - V Kurshetsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - G Lamanna
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Lanfranchi
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - E Lari
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - G Latino
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - P Laycock
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - C Lazzeroni
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - G Lehmann Miotto
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - M Lenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - E Leonardi
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lichard
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Litov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - R Lollini
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - D Lomidze
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - A Lonardo
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - P Lubrano
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Lupi
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - N Lurkin
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - D Madigozhin
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - I Mannelli
- Scuola Normale Superiore e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Mapelli
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - F Marchetto
- INFN, Sezione di Torino, I-10125 Torino, Italy
| | - R Marchevski
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - S Martellotti
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - P Massarotti
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - K Massri
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - E Maurice
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - M Medvedeva
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - A Mefodev
- Institute for Nuclear Research of the Russian Academy of Sciences, 117312 Moscow, Russia
| | - E Menichetti
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Migliore
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - E Minucci
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Mirra
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - M Misheva
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - N Molokanova
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Moulson
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - S Movchan
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - M Napolitano
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - I Neri
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - F Newson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Norton
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - M Noy
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - T Numao
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - V Obraztsov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Ostankov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - S Padolski
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - R Page
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - V Palladino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Parenti
- Dipartimento di Fisica e Astronomia dell'Università e INFN, Sezione di Firenze, I-50019 Sesto Fiorentino, Italy
| | - C Parkinson
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - E Pedreschi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - M Pepe
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Perrin-Terrin
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - L Peruzzo
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - P Petrov
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - Y Petrov
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - F Petrucci
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Piandani
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - M Piccini
- INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - J Pinzino
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - I Polenkevich
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - L Pontisso
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - Yu Potrebenikov
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | | | - M Raggi
- Dipartimento di Fisica, Sapienza Università di Roma e INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - A Romano
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - P Rubin
- George Mason University, Fairfax, Virginia 22030, USA
| | - G Ruggiero
- University of Lancaster, Lancaster LA1 4YW, United Kingdom
| | - V Ryjov
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - A Salamon
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - C Santoni
- Dipartimento di Fisica e Geologia dell'Università e INFN, Sezione di Perugia, I-06100 Perugia, Italy
| | - G Saracino
- Dipartimento di Fisica "Ettore Pancini" e INFN, Sezione di Napoli, I-80126 Napoli, Italy
| | - F Sargeni
- INFN, Sezione di Roma Tor Vergata, I-00133 Roma, Italy
| | - S Schuchmann
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - V Semenov
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - A Sergi
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - A Shaikhiev
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - S Shkarovskiy
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| | - D Soldi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Torino, I-10125 Torino, Italy
| | - M Sozzi
- Dipartimento di Fisica dell'Università e INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - T Spadaro
- Laboratori Nazionali di Frascati, I-00044 Frascati, Italy
| | - F Spinella
- INFN, Sezione di Pisa, I-56100 Pisa, Italy
| | - A Sturgess
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - V Sugonyaev
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - J Swallow
- University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom
| | - S Trilov
- University of Bristol, Bristol BS8 1TH, United Kingdom
| | - P Valente
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - B Velghe
- TRIUMF, Vancouver, British Columbia V6T 2A3, Canada
| | - S Venditti
- CERN, European Organization for Nuclear Research, CH-1211 Geneva 23, Switzerland
| | - P Vicini
- INFN, Sezione di Roma I, I-00185 Roma, Italy
| | - R Volpe
- Université Catholique de Louvain, B-1348 Louvain-La-Neuve, Belgium
| | - M Vormstein
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - H Wahl
- Dipartimento di Fisica e Scienze della Terra dell'Università e INFN, Sezione di Ferrara, I-44122 Ferrara, Italy
| | - R Wanke
- Institut für Physik and PRISMA Cluster of Excellence, Universität Mainz, D-55099 Mainz, Germany
| | - B Wrona
- University of Liverpool, Liverpool L69 7ZE, United Kingdom
| | - O Yushchenko
- Institute for High Energy Physics-State Research Center of Russian Federation, 142281 Protvino (MO), Russia
| | - M Zamkovsky
- Charles University, 116 36 Prague 1, Czech Republic
| | - A Zinchenko
- Joint Institute for Nuclear Research, 141980 Dubna (MO), Russia
| |
Collapse
|
34
|
Giorgi M, Desikan R, van der Graaf PH, Kierzek AM. Application of quantitative systems pharmacology to guide the optimal dosing of COVID-19 vaccines. CPT Pharmacometrics Syst Pharmacol 2021; 10:1130-1133. [PMID: 34331834 PMCID: PMC8420530 DOI: 10.1002/psp4.12700] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 07/23/2021] [Accepted: 07/27/2021] [Indexed: 11/07/2022] Open
Abstract
Optimal use and distribution of coronavirus disease 2019 (COVID-19) vaccines involves adjustments of dosing. Due to the rapidly evolving pandemic, such adjustments often need to be introduced before full efficacy data are available. As demonstrated in other areas of drug development, quantitative systems pharmacology (QSP) is well placed to guide such extrapolation in a rational and timely manner. Here, we propose for the first time how QSP can be applied in the context of COVID-19 vaccine development.
Collapse
|
35
|
Sartini I, Łebkowska-Wieruszewska B, Lisowski A, Poapolathep A, Sitovs A, Giorgi M. Doxycycline pharmacokinetics in geese. J Vet Pharmacol Ther 2021; 44:975-981. [PMID: 34318509 PMCID: PMC9291109 DOI: 10.1111/jvp.13002] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2021] [Revised: 06/28/2021] [Accepted: 07/13/2021] [Indexed: 11/30/2022]
Abstract
The study aims to describe the pharmacokinetics of doxycycline after a single intravenous and oral dose (20 mg/kg) in geese. In addition, two multiple‐dose simulations have been performed to investigate the predicted plasma concentration after either a 10 or 20 mg/kg daily administration repeated consecutively for 5 days. Ten geese were enrolled in a two‐phase cross‐over study with a washout period of two weeks. All animals were treated intravenously and orally with doxycycline, and blood samples were collected up to 48 h after drug administration. Sample analysis was performed using a validated HPLC‐UV method. A non‐compartmental approach was used to evaluate the pharmacokinetic parameters of the drug. A long elimination half‐life was observed (13 h). The area under the curve was statistically different between the two treatments, with the oral bioavailability being moderate (43%). The pharmacokinetic/pharmacodynamic index (%T>MIC) during the 48 h treatment period in the present study (71%) suggests that doxycycline appears to have therapeutic efficacy against some Mycoplasma species in the goose. The multiple‐dose simulations showed a low accumulation index. A dosage of 10 mg/kg/day for 5 days seemed to be adequate for a good therapeutic efficacy without reaching unnecessarily high plasma concentrations.
Collapse
Affiliation(s)
- Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Andrejs Sitovs
- Department of Pharmacology, Riga Stradins University, Riga, Latvia
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy.,Department of Veterinary Medicine, School of Veterinary Sciences, University of Sassari, Sassari, Italy
| |
Collapse
|
36
|
Łebkowska-Wieruszewska B, Ziółkowski H, Sartini I, Lisowski A, Kowalski CJ, Poapolathep A, Giorgi M. Agomelatine: A novel melatonergic antidepressant. Method validation and first exploratory pharmacokinetic study in fasted and fed dogs. Res Vet Sci 2021; 139:140-144. [PMID: 34303122 DOI: 10.1016/j.rvsc.2021.07.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 07/13/2021] [Accepted: 07/14/2021] [Indexed: 11/19/2022]
Abstract
Agomelatine is a novel melatonergic antidepressant, with a non-monoaminergic mechanism of action. The aim of this study was to evaluate its plasma concentrations after a single oral dose of 300 mg/dog in fasted and fed status. The research was carried out in 6 adult healthy Labrador dogs according to a randomized open, single-dose, two-treatment, two-phase, paired 2 × 2 cross-over study. At the end of the study all the animals had received the drug in fasted and fed conditions. The drug concentrations were detected in plasma by a validated LC-MS/MS analytical method. The plasma concentrations of agomelatine were found to be extremely variable in both groups as well as the pharmacokinetic profiles. Due to these variable findings the only reliable pharmacokinetic parameters were assessed as Cmax (31.8 vs 15.7 ng/mL), Tmax (0.75 vs 4 h) and AUC (155 vs 52 ng h/mL) in fasted and fed status, respectively. Unfortunately, as a pioneer study, the small animal sample size used along with the unanticipated variability did not allow to neither statistically estimate if food can affect the pharmacokinetics of agomelatine nor recommend agomelatine for off-label therapies in canine species. Further studies are warranted to clarify this issue.
Collapse
Affiliation(s)
- Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Hubert Ziółkowski
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13, 10-718 Olsztyn, Poland
| | - Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Italy
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Cezary J Kowalski
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Italy; Department of Veterinary Medicine, University of Sassari, Italy.
| |
Collapse
|
37
|
Vercelli C, Pasquetti M, Giovannetti G, Visioni S, Re G, Giorgi M, Gambino G, Peano A. In vitro and in vivo evaluation of a new phytotherapic blend to treat acute externa otitis in dogs. J Vet Pharmacol Ther 2021; 44:910-918. [PMID: 34258792 PMCID: PMC9290716 DOI: 10.1111/jvp.13000] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2021] [Revised: 06/19/2021] [Accepted: 06/29/2021] [Indexed: 01/13/2023]
Abstract
Canine otitis externa is frequently encountered in veterinary practice, caused by primary factors with bacteria and yeast overgrowth acting as secondary and perpetuating factors. The pharmacological support includes anti-inflammatory, antimicrobials, and antimycotic drugs, but therapeutic failure and antimicrobial resistance are leading to alternative strategies based on phytotherapic products. This study aimed to evaluate an essential oil blend (Otogen® ) to treat otitis externa in dogs. The experimental design was divided in: (a) an in vitro approach, based on the European Normative UNI EN 1275:2006, to assess the efficacy of the product against the most frequently isolated microorganisms during otitis externa. (b) an in vivo part, 12 owned dogs presenting with acute otitis externa were enrolled. A significant growth reduction (>99.9%) of Malassezia pachydermatis and Candida albicans after 15 min of contact and Pseudomonas aeruginosa after 1 h of incubation was recorded. For Staphylococcus pseudintermedius, 50% of growth reduction were appreciated after 15 min. Results obtained in vivo after 7 days of blend administration, noted a significant improvement of all the considered parameters (most important were head shaking, erythema, and scraping). The results obtained may support the usefulness of the tested phytotherapic blend to manage acute otitis externa in dogs.
Collapse
Affiliation(s)
- Cristina Vercelli
- Department of Veterinary Science of Turin, University of Turin, Turin, Italy
| | - Mario Pasquetti
- Department of Veterinary Science of Turin, University of Turin, Turin, Italy
| | | | - Sara Visioni
- Department of Veterinary Science of Turin, University of Turin, Turin, Italy
| | - Giovanni Re
- Department of Veterinary Science of Turin, University of Turin, Turin, Italy
| | - Mario Giorgi
- Department of Veterinary Science of Pisa, University of Pisa, Pisa, Italy
| | - Graziana Gambino
- Department of Veterinary Science of Turin, University of Turin, Turin, Italy
| | - Andrea Peano
- Department of Veterinary Science of Turin, University of Turin, Turin, Italy
| |
Collapse
|
38
|
Sadati NY, Youssefi MR, Hosseinifard SM, Tabari MA, Giorgi M. Pharmacokinetics and pharmacodynamics of single and multiple-dose levamisole in belugas (Huso huso): Main focus on immunity responses. Fish Shellfish Immunol 2021; 114:152-160. [PMID: 33915293 DOI: 10.1016/j.fsi.2021.04.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 04/15/2021] [Accepted: 04/17/2021] [Indexed: 06/12/2023]
Abstract
The pharmacokinetics of levamisole were determined in the belugas after single intravascular (IV), and single and multiple-dose oral by feed administrations. Also, the effect of levamisole (LVM) on the stress and immune responses of belugas were assessed. One hundred-fourteen healthy belugas in 4 different groups received single LVM administration at the doses of 50 and 100 mg/kg via IV and oral routes. A separate group of 24 belugas were administered oral LVM at the dose of 100 mg/kg for 5 days. Blood samples were collected at different time points after administrations to measure plasma concentrations of LVM by a validated high-performance liquid chromatography (HPLC) assay. For immunological evaluations, a total of 126 belugas received 50 and 100 mg/kg LVM via medicated feed for 5 days or served as the control without any medication; blood samples were recovered on day 0, 1, 3, 5, 7, 10, and 14 to measure hemolytic activity of the complement system (HAC50), serum lysozyme activity, serum antibacterial activity, glucose, cortisol, total protein, albumin and C3 contents. In the single-dose administration, quantified LVM concentrations were dose-dependent and the oral bioavailability was in the range of 43.2-49.6%. In the multiple-dose administration, the peak plasma concentration at the steady state was 45.2 mg/ml, and accumulation ratio was calculated as 3.6. In the immunological study, LVM especially at the dose of 100 mg/kg increased HAC50, lysozyme and antibacterial activity in the sera of treated fish. No significant effect of LVM on glucose and albumin content was observed, but cortisol levels decreased and C3 content was increased, more significantly by LVM at the dose of 100 mg/kg. Our results indicate that LVM is well absorbed after oral administration and reached to concentrations that can affect stress indicators and improve immune responses in belugas.
Collapse
Affiliation(s)
- NadAli Yousefi Sadati
- Department of Aquaculture and Animal Sciences, Babol Branch, Islamic Azad University, Babol, Iran
| | - Mohammad Reza Youssefi
- Department of Veterinary Parasitology, Babol Branch, Islamic Azad University, Babol, Iran.
| | - Seyed Mehdi Hosseinifard
- Department of Aquaculture and Animal Sciences, Babol Branch, Islamic Azad University, Babol, Iran.
| | | | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Pisa, Italy
| |
Collapse
|
39
|
Sartini I, Łebkowska-Wieruszewska B, Lisowski A, Poapolathep A, Llewelyn V, Giorgi M. Single intravenous and oral pharmacokinetics of danofloxacin in the goat. Small Rumin Res 2021. [DOI: 10.1016/j.smallrumres.2021.106393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
40
|
Abstract
Grapiprant is the pioneer member of the novel piprant class, a potent and specific antagonist of the prostaglandin E2 receptor 4. It has been approved in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in dogs at the dose regimen of 2 mg/kg once a day by the FDA and EMA (for pain only) in 2016 and 2018, respectively. The aim of this narrative review was to report the analytical methods, pharmacokinetics, pharmacodynamics and safety of grapiprant in several animal species using the best available published scientific evidence. In conclusion, most of the analytical methods proposed for grapiprant detection are simple, reliable, sensitive and validated. The pharmacokinetics show discrepancies between animal species. The therapeutic efficacy seems more suited to chronic rather than acute pain.
Collapse
Affiliation(s)
- Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy.,PhD School, Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| |
Collapse
|
41
|
Sitovs A, Sartini I, Giorgi M. Levofloxacin in veterinary medicine: a literature review. Res Vet Sci 2021; 137:111-126. [PMID: 33964616 DOI: 10.1016/j.rvsc.2021.04.031] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 03/26/2021] [Accepted: 04/27/2021] [Indexed: 01/10/2023]
Abstract
A potent third-generation antimicrobial fluoroquinolone drug, levofloxacin was introduced into human clinical practice in 1993. Levofloxacin is also used in veterinary medicine, however its use is limited: it is completely banned for veterinary use in the EU, and used extralabel in only companion animals in the USA. Since its introduction to clinical practice, many studies have been published on levofloxacin in animal species, including pharmacokinetic studies, tissue drug depletion, efficacy, and animal microbial isolate susceptibility to levofloxacin. This literature overview highlights the most clinically relevant and scientifically important levofloxacin studies linked to the field of veterinary medicine.
Collapse
Affiliation(s)
- Andrejs Sitovs
- Department of Pharmacology, Rīga Stradiņš University, Riga, Latvia.
| | - Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, San Piero a Grado, Pisa, Italy
| |
Collapse
|
42
|
Orio M, Bindra JK, van Tol J, Giorgi M, Dalal NS, Bertaina S. Quantum dynamics of Mn 2+ in dimethylammonium magnesium formate. J Chem Phys 2021; 154:154201. [PMID: 33887944 DOI: 10.1063/5.0046984] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Dimethylammonium magnesium formate, [(CH3)2NH2][Mg(HCOO)3] or DMAMgF, is a model used to study high temperature hybrid perovskite-like dielectrics. This compound displays an order-disorder phase transition at about 260 K. Using multifrequency electron spin resonance in continuous wave and pulsed modes, we herein present the quantum dynamics of the Mn2+ ion probe in DMAMgF. In the high temperature paraelectric phase, we observe a large distribution of the zero field splitting that is attributed to the high local disorder and further supported by density functional theory computations. In the low temperature ferroelastic phase, a single structure phase is detected and shown to contain two magnetic structures. The complex electron paramagnetic resonance signals were identified by means of the Rabi oscillation method combined with the crystal field kernel density estimation.
Collapse
Affiliation(s)
- M Orio
- CNRS, Aix-Marseille Université, Centrale Marseille, iSm2, Institut des Sciences Moléculaires de Marseille, Marseille, France
| | - J K Bindra
- Department of Chemistry, Florida State University, Tallahassee, Florida 32310, USA
| | - J van Tol
- The National High Magnetic Field Laboratory, Tallahassee, Florida 32310, USA
| | - M Giorgi
- Aix Marseille Université, CNRS, Centrale Marseille, FSCM, Spectropole, Marseille, France
| | - N S Dalal
- Department of Chemistry, Florida State University, Tallahassee, Florida 32310, USA
| | - S Bertaina
- CNRS, Aix-Marseille Université, IM2NP (UMR 7334), Institut Matériaux Microélectronique et Nanosciences de Provence, Marseille, France
| |
Collapse
|
43
|
Fanelli D, Tesi M, Rota A, Beltramo M, Conte G, Giorgi M, Barsotti G, Camillo F, Panzani D. hCG is more effective than the GnRH agonist buserelin for inducing the first ovulation of the breeding season in mares. Equine Vet J 2021; 54:306-311. [PMID: 33884659 PMCID: PMC9291952 DOI: 10.1111/evj.13455] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Revised: 02/15/2021] [Accepted: 04/03/2021] [Indexed: 12/01/2022]
Abstract
Background Human Chorionic Gonadotropin (hCG) and Gonadotropin Releasing Hormone agonists (GnRHa) are routinely used to induce ovulation in mares. However, GnRHa efficacy in transitional mares has been suggested to be low. Objectives The aims of this study were as follows: (a) to compare the efficacy of hCG and GnRHa in inducing the first ovulation of the breeding season and (b) to evaluate the correlation between ovulatory response, uterine oedema and teasing score at the time of treatment during the early or late transitional phase. Study design Randomised controlled superiority trial. Methods Mares in winter anoestrus were treated with sulpiride when at least two follicles reached a diameter of 25 mm. The day after the follicle reached 35 mm in diameter, mares in oestrus were treated with GnRHa buserelin (N = 29) or hCG (N = 33) and checked daily for ovulation. Results More mares (30/33, 90.1%) ovulated when the first ovulation after winter anoestrus was induced with hCG, than with GnRHa, (11/29, 38.0%) (P = .0001). Ovulation rate was lower in mares that did not show uterine oedema and full acceptance of the teaser stallion for at least three days before the treatment (32/41, 78% vs 9/21, 42.9%) P = .01. Main limitations Plasma LH and oestrogen concentrations were not performed. Conclusions These results demonstrate that hCG was more effective than GnRHa for inducing ovulation in the first cycle after winter anoestrus. Uterine oedema and behavioural signs of oestrus, for at least three days before the treatment, were predictors for a positive response to ovulation induction.
Collapse
Affiliation(s)
- Diana Fanelli
- Dipartimento di Scienze Veterinarie, Università di Pisa, Pisa, Italy
| | - Matteo Tesi
- Dipartimento di Scienze Veterinarie, Università di Pisa, Pisa, Italy
| | - Alessandra Rota
- Dipartimento di Scienze Veterinarie, Università di Pisa, Pisa, Italy
| | - Massimiliano Beltramo
- UMR Physiologie de la Reproduction et des Comportements (INRA, UMR85, CNRS, UMR7247, Université de Tours, IFCE), Nouzilly, France
| | - Giuseppe Conte
- Department of Agriculture, Food and Environment, University of Pisa, Pisa, Italy
| | - Mario Giorgi
- Dipartimento di Scienze Veterinarie, Università di Pisa, Pisa, Italy
| | - Giovanni Barsotti
- Dipartimento di Scienze Veterinarie, Università di Pisa, Pisa, Italy
| | - Francesco Camillo
- Dipartimento di Scienze Veterinarie, Università di Pisa, Pisa, Italy
| | - Duccio Panzani
- Dipartimento di Scienze Veterinarie, Università di Pisa, Pisa, Italy
| |
Collapse
|
44
|
Tabari MA, Poźniak B, Youssefi MR, Roudaki Sarvandani MR, Giorgi M. Comparative pharmacokinetics of metronidazole in healthy and Trichomonas gallinae infected pigeons ( Columba livia, var. domestica). Br Poult Sci 2021; 62:485-491. [PMID: 33491469 DOI: 10.1080/00071668.2021.1881043] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
1. This study investigated the pharmacokinetics of metronidazole after intravenous (i.v.) and oral administration to healthy and experimentally Trichomonas gallinae-infected pigeons, and determined the in vitro antiprotozoal activity of metronidazole against T. gallinae.2. Twelve pigeons which were experimentally infected to T. gallinae and twelve healthy pigeons received metronidazole at the dose of 25 mg/kg by oral or i.v. administration. Serial blood sampling was used for pharmacokinetic analysis. The metronidazole minimum lethal concentration (MLC) and the concentration killing 50% of the trophozoites (LC50) in the culture media were determined.3. In vitro data showed that the 24 h LC50 and MLC of metronidazole were 0.31 and 25 µg/ml, respectively. In vivo results showed no statistical differences between pharmacokinetics in infected and non-infected pigeons for both routes of administration. The area under the curve was statistically higher after the i.v. administration in both infected and healthy pigeons. The mean oral bioavailability was similar in the infected (83.8%) and the healthy (81.5%) birds.4. In conclusion, the pharmacokinetics of metronidazole in pigeons was not affected by experimentally-induced trichomoniasis. Despite in vitro susceptibility testing, which showed probable resistance of the isolated T. gallinae to metronidazole, five-day oral treatment of infected pigeons with 25 mg/kg metronidazole twice a day resulted in total eradication of trophozoites recovered in crop lavage of infected birds.
Collapse
Affiliation(s)
- M A Tabari
- Faculty of Veterinary Medicine, Amol University of Special Modern Technologies, Amol, Iran
| | - B Poźniak
- Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, Wrocław, Poland
| | - M R Youssefi
- Department of Veterinary Parasitology, Babol Branch, Islamic Azad University, Babol, Iran
| | | | - M Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy.,Veterinary Medicine PhD School, University of Sassari, Sassari, Italy
| |
Collapse
|
45
|
Pietruk K, Gbylik-Sikorska M, Łebkowska-Wieruszewska B, Gajda A, Giorgi M, Sartini I, Jedziniak P. Development of a Multimatrix UHPLC-MS/MS Method for the Determination of Paracetamol and Its Metabolites in Animal Tissues. Molecules 2021; 26:molecules26072046. [PMID: 33918518 PMCID: PMC8038326 DOI: 10.3390/molecules26072046] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 03/29/2021] [Accepted: 03/30/2021] [Indexed: 11/16/2022] Open
Abstract
Paracetamol/acetaminophen (APAP) is one of the most popular pharmacologically active substances used as an analgesic and antipyretic agent. The metabolism of this drug occurs in the liver and leads to the formation of two main metabolites-glucuronic acid and sulfate derivate. Despite the wide use of paracetamol in veterinary medicine, a handful of analytical methods were published for the determination of paracetamol residues in animal tissues. In this paper, a multimatrix method has been developed for the determination of paracetamol and two metabolites-paracetamol sulfate (PS) and p-Acetamidophenyl β-D-glucuronide (PG). A validation procedure was conducted to verify method reliability and fit purpose as a tool for analyzing acetaminophen and metabolites in muscle, liver, lung, and kidney samples from different species of animals. Established validation parameters were in agreement with acceptable criteria laid by the European legislation. The initial significant matrix effect was successfully reduced by implementing an internal standard-4-Acetamidophenyl β-D-glucuronide-d3 (PG-d3, IS). The usefulness of the developed method was verified by analyzing samples from an experiment in which paracetamol was administrated to geese.
Collapse
Affiliation(s)
- Konrad Pietruk
- Department of Pharmacology and Toxicology, National Veterinary Research Institute, 24-100 Pulawy, Poland; (M.G.-S.); (A.G.); (P.J.)
- Correspondence: ; Tel.: +48 81-889-3169
| | - Małgorzata Gbylik-Sikorska
- Department of Pharmacology and Toxicology, National Veterinary Research Institute, 24-100 Pulawy, Poland; (M.G.-S.); (A.G.); (P.J.)
| | - Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, 20-950 Lublin, Poland;
| | - Anna Gajda
- Department of Pharmacology and Toxicology, National Veterinary Research Institute, 24-100 Pulawy, Poland; (M.G.-S.); (A.G.); (P.J.)
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, 56126 Pisa, Italy;
- Department of Veterinary Medicine, PhD School, University of Sassari, 07100 Sassari, Italy;
| | - Irene Sartini
- Department of Veterinary Medicine, PhD School, University of Sassari, 07100 Sassari, Italy;
| | - Piotr Jedziniak
- Department of Pharmacology and Toxicology, National Veterinary Research Institute, 24-100 Pulawy, Poland; (M.G.-S.); (A.G.); (P.J.)
| |
Collapse
|
46
|
Martelli S, Giorgi M, Dall' Ara E, Perilli E. Damage tolerance and toughness of elderly human femora. Acta Biomater 2021; 123:167-177. [PMID: 33454384 DOI: 10.1016/j.actbio.2021.01.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Revised: 12/22/2020] [Accepted: 01/09/2021] [Indexed: 11/30/2022]
Abstract
Observations of elastic instability of trabecular bone cores supported the analysis of cortical thickness for predicting bone fragility of the hip in people over 60 years of age. Here, we falsified the hypothesis that elastic instability causes minimal energy fracture by analyzing, with a micrometric resolution, the deformation and fracture behavior of entire femora. Femur specimens were obtained from elderly women aged between 66 - 80 years. Microstructural images of the proximal femur were obtained under 3 - 5 progressively increased loading steps and after fracture. Bone displacements, strain, load bearing and energy absorption capacity were analyzed. Elastic instability of the cortex appeared at early loading stages in regions of peak compression. No elastic instability of trabecular bone was observed. The subchondral bone displayed local crushing in compression at early loading steps and progressed to 8 - 16% compression before fracture. The energy absorption capacity was proportional to the displacement. Stiffness decreased to near-zero values before fracture. Three-fourth of the fracture energy (10.2 - 20.2 J) was dissipated in the final 25% force increment. Fracture occurred in regions of peak tension and shear, adjacent to the location of peak compression, appearing immediately before fracture. Minimal permanent deformation was visible along the fracture surface. Elastic instability modulates the interaction between cortical and trabecular bone promoting an elastically stable fracture behavior of the femur organ, load bearing capacity, toughness, and damage tolerance. These findings will advance current methods for predicting hip fragility.
Collapse
Affiliation(s)
- Saulo Martelli
- School of Mechanical, Medical and Process Engineering, Queensland University of Technology, Brisbane, Australia; Medical Device Research Institute, College of Science and Engineering, Flinders University, Adelaide SA, Australia.
| | - Mario Giorgi
- Department of Oncology and Metabolism and Insigneo Institute for in Silico Medicine, University of Sheffield, Sheffield, UK; Certara QSP, Certara UK Limited, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, UK
| | - Enrico Dall' Ara
- Department of Oncology and Metabolism and Insigneo Institute for in Silico Medicine, University of Sheffield, Sheffield, UK
| | - Egon Perilli
- Medical Device Research Institute, College of Science and Engineering, Flinders University, Adelaide SA, Australia
| |
Collapse
|
47
|
Tourdot S, Abdolzade-Bavil A, Bessa J, Broët P, Fogdell-Hahn A, Giorgi M, Jawa V, Kuranda K, Legrand N, Pattijn S, Pedras-Vasconcelos JA, Rudy A, Salmikangas P, Scott DW, Snoeck V, Smith N, Spindeldreher S, Kramer D. 10 th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals. MAbs 2021; 12:1725369. [PMID: 32063088 PMCID: PMC7039638 DOI: 10.1080/19420862.2020.1725369] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Therapeutic proteins and emerging gene and cell-based therapies are attractive therapeutic tools for addressing unmet medical needs or when earlier conventional treatment approaches failed. However, the development of an immune response directed against therapeutic agents is a significant concern as it occurs in a substantial number of cases across products and indications. The specific anti-drug antibodies that develop can lead to safety adverse events as well as inhibition of drug activity or accelerated clearance, both phenomena resulting in loss of treatment efficacy. The European Immunogenicity Platform (EIP) is a meeting place for experts and newcomers to the immunogenicity field, designed to stimulate discussion amongst scientists across industry and academia, encourage interactions with regulatory agencies and share knowledge and the state-of-the-art of immunogenicity sciences with the broader scientific community. Here we report on the main topics covered during the EIP 10th Open Symposium on Immunogenicity of Biopharmaceuticals held in Lisbon, 26–27 February 2019, and the 1-d training course on practical and regulatory aspects of immunogenicity held ahead of the conference. These main topics included immunogenicity testing, clinical relevance of immunogenicity, immunogenicity prediction, regulatory aspects, tolerance induction as a mean to mitigate immunogenicity and immunogenicity in the context of gene therapy.
Collapse
Affiliation(s)
- S Tourdot
- BioMedicine Design, Pfizer Inc, Andover, MA, USA
| | - A Abdolzade-Bavil
- Large Molecule Bioanalytical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Hoffmann-La Roche Ltd, Germany
| | - J Bessa
- Pharmaceutical Sciences, Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Hoffmann-La Roche Ltd, Basel, Switzerland
| | - P Broët
- Faculty of Medicine Paris-Saclay, Orsay, France
| | - A Fogdell-Hahn
- Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden
| | - M Giorgi
- Certara QSP, Certara UK Limited, UK
| | - V Jawa
- Predictive and Clinical Immunogenicity, PPDM, Merck & Co, Kenilworth, NJ, USA
| | - K Kuranda
- Translational Department, Sparks Therapeutics, Philadelphia, PA, USA
| | | | | | | | - A Rudy
- HEXAL AG, Holzkirchen, Germany
| | | | - D W Scott
- Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - V Snoeck
- Translational Biomarkers and Bioanalysis, UCB Biopharma SRL, Braine-l'Alleud, Belgium
| | | | | | - D Kramer
- Sanofi R&D, Translational Medicine & Early Development, Sanofi, Frankfurt am Main, Germany
| |
Collapse
|
48
|
Sartini I, Łebkowska-Wieruszewska B, Lisowski A, Poapolathep A, Giorgi M. Danofloxacin pharmacokinetics and tissue residues in Bilgorajska geese. Res Vet Sci 2021; 136:11-17. [PMID: 33556838 DOI: 10.1016/j.rvsc.2021.01.017] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 01/19/2021] [Accepted: 01/22/2021] [Indexed: 02/07/2023]
Abstract
Danofloxacin is a fluoroquinolone developed for veterinary medicine and used in avian species for the treatment of numerous bacterial infections. However, no pharmacokinetic data have been reported in geese. The aim of the study was three-fold: (i) to evaluate the pharmacokinetics of danofloxacin in geese after single oral (PO) and intravenous (IV) administrations; (ii) to define its residue depletion profile in different goose tissues, and (iii) to recreate a multiple-dose simulation in the practical context of large-scale breeding. Twenty-four healthy geese were randomly divided in three groups each composed of eight animals. Group 1 received danofloxacin IV (5 mg/kg) and groups 2 and 3 were treated PO with the same dose. Blood was collected until 24 h (IV; group 1) and 48 h (PO; group 2) after administration. Two animals from group 3 were sacrificed at 6, 10, 24 and 48 h to collect samples of muscle, heart, kidney, liver, and lung. Danofloxacin was quantified in each matrix using a validated high-performance liquid chromatography method with spectrofluorimetric detection and the pharmacokinetic analysis was performed using non-compartmental and compartmental approaches. Danofloxacin showed a moderate elimination half-life (6.61 h), a slow clearance (0.35 mL/g*h) and a large volume of distribution (1.46 mL/g). The peak plasma concentration after PO administration and the time to reach it were 0.96 μg/mL and 1.70 h, respectively. The oral bioavailability was moderate (58%). Higher residue concentration was found in liver and kidney, compared to the other tissues. If the AUC(0-24) value found in the present study is included in the pharmacokinetic/pharmacodynamic index (AUC(0-24)/MIC) for the prediction of fluoroquinolones' efficacy, danofloxacin seems to be effective in geese against gram-negative bacteria with a minimum inhibitory concentration (MIC) < 0.076 μg/mL and against S. pneumoniae with a MIC < 0.29 μg/mL after a single PO dose of 5 mg/kg. Liver and kidney showed the highest drug tissue penetration value, with an explorative withdrawal time of 2.6 and 3.8 days, respectively. A practical multiple-dose regimen simulation does not lead to significant plasma drug accumulation.
Collapse
Affiliation(s)
- Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | | | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Faculty of Veterinary Medicine, Department of Pharmacology, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy; School of Veterinary Sciences, Department of Veterinary Medicine, University of Sassari, Sassari, Italy.
| |
Collapse
|
49
|
Łebkowska-Wieruszewska B, Gbylik-Sikorska M, Gajda A, Sartini I, Lisowski A, Poapolathep A, Giorgi M. Cebranopadol, a novel first-in-class drug candidate: Method validation and first exploratory pharmacokinetic study in rabbits. J Vet Pharmacol Ther 2021; 44:516-521. [PMID: 33491237 DOI: 10.1111/jvp.12948] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Revised: 01/04/2021] [Accepted: 01/08/2021] [Indexed: 01/11/2023]
Abstract
Cebranopadol is a novel, centrally acting, potent, first-in-class analgesic drug candidate with a unique mode of action that combines nociceptin/orphanin FQ peptide receptor and opioid peptide receptor agonism. The present study aimed to develop and validate a novel UHPLC-MS/MS method to quantify cebranopadol in rabbit plasma and to assess its pharmacokinetics in rabbits after subcutaneous (s.c.) administration. Twelve adult females were administered with 200 µg/kg s.c. injection. Blood samples were withdrawn at 15, 30 and 45 min and 1, 1.5, 2, 4, 6, 8, 10 and 24 hr after administration. The plasma samples were extracted with a liquid/liquid extraction. The new analytical method complied with the EMA requirements for the bioanalytical method validation. The method was selective, repeatable, accurate, precise and robust with a lower limit of quantification of 0.1 ng/ml. In all the rabbits, cebranopadol was quantifiable from 0.25 to 10 hr. Mean Cmax and Tmax were 871 ng/ml and 0.25 hr, respectively. Further studies including the i.v. administration are necessary to fully evaluate the pharmacokinetic features of this novel active compound.
Collapse
Affiliation(s)
- Beata Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | | | - Anna Gajda
- Department of Pharmacology and Toxicology, National Veterinary Research Institute, Puławy, Poland
| | - Irene Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - Andrzej Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - Amnart Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - Mario Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy.,PhD school, Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| |
Collapse
|
50
|
Sartini I, Łebkowska-Wieruszewska B, Sitovs A, Lisowski A, Poapolathep A, Giorgi M. Levofloxacin pharmacokinetics and tissue residue concentrations after oral administration in Bilgorajska geese. Br Poult Sci 2020; 62:193-198. [PMID: 33121260 DOI: 10.1080/00071668.2020.1842855] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
1. The aim of this study was to assess the pharmacokinetics of levofloxacin, a third-generation fluoro-quinolone antimicrobial drug, in geese (n = 26) after either single intravenous or oral administration, and to evaluate the depletion profile in goose muscle, heart, liver, kidney and lung after a single oral dose.2. The pharmacokinetic study involved 16 geese which were randomly divided into two groups (n = 8/group), the first received levofloxacin (2 mg/kg) intravenously while the second was treated with orally (5 mg/kg). The tissue depletion study involved 10 geese which were dosed orally (5 mg/kg) and two animals were killed at different time-points in order to collect the selected tissues. Levofloxacin was quantified in all the matrices tested by a validated high-performance liquid chromatography (HPLC) method, using a spectrofluorimetric detector. The pharmacokinetics were analysed using a non-compartmental model.3. Plasma concentrations were quantified after up to 24 h in animals administered intravenously and up to 48 h after oral treatment. Levofloxacin was rapidly absorbed after oral administration (Tmax = 0.38 h) showing high bioavailability (95.57 ± 20.61%). The drug showed a moderate volume of distribution (1.40 ± 0.28 ml/g) and rapid clearance (0.28 ± 0.06 ml/g/h). No statistical differences in estimates were found between the two different administration methods (P > 0.05). Drug residues were highest at 6 h and decreased constantly up to 48 h in all the selected tissues. Liver and kidney had the highest levofloxacin concentrations.4. According to the pharmacokinetic/pharmacodynamic surrogate index (AUC/MIC) the levofloxacin dose regimen (after oral administration) used in the present study could be active against bacteria at a minimum inhibitory concentration (MIC) > 0.24 μg/ml in geese. In addition, drug accumulation in the liver might be controlled using an estimated preliminary withdrawal time of 90 h.
Collapse
Affiliation(s)
- I Sartini
- Department of Veterinary Medicine, University of Sassari, Sassari, Italy
| | - B Łebkowska-Wieruszewska
- Department of Pharmacology, Toxicology and Environmental Protection, University of Life Sciences, Lublin, Poland
| | - A Sitovs
- Department of Pharmacology, Riga Stradins University, Riga, Latvia
| | - A Lisowski
- Institute of Animal Breeding and Biodiversity Conservation, University of Life Sciences, Lublin, Poland
| | - A Poapolathep
- Department of Pharmacology, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand
| | - M Giorgi
- Department of Veterinary Sciences, University of Pisa, Pisa, Italy
| |
Collapse
|